

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

0623.0890000/EKS/PSC

U.S. APPLICATION NO. (IF KNOWN, SEE 37 C.F.R. § 1.5)

To be assigned 099/646679

INTERNATIONAL APPLICATION NO.

PCT/GB99/00905

INTERNATIONAL FILING DATE

22 March 1999

PRIORITY DATE CLAIMED

20 March 1998

TITLE OF INVENTION

Signal Transduction Protein Involved in Plant Dehiscence

APPLICANT(S) FOR DO/EO/US

Wyatt, Paul; Roberts, Jeremy Alan; and Whitelaw, Catherine

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 372(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☒ A copy of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment and submission of sequence listing.
 - ☒ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: Authorization To Treat A Reply As Incorporating An Extension Of Time Under 37 C.F.R. § 1.136(a)(3) (in duplicate); and Claim for Priority Under 35 U.S.C. § 119(a)-(d) In Utility Application, with Certified Priority Document attached.

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.50) To be assigned 09/646679	INTERNATIONAL APPLICATION NO PCT/GB99/00905	ATTORNEY'S DOCKET NUMBER 0623.0890000/EKS/PSC
--	--	--

17. <input checked="" type="checkbox"/> The following fees are submitted:	CALCULATIONS PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$ 96.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>	<div style="border: 1px solid black; height: 150px; width: 100%;"></div>
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	<div style="border: 1px solid black; height: 40px; width: 100%;"></div>

Claims	Number Filed	Number Extra	Rate			
Total Claims	29 - 20 =	9	X \$18.00	\$ 162.00		
Independent Claims	3 - 3 =	0	X \$78.00	\$ 0.00		
Multiple dependent claim(s) (if applicable)			+ \$260.00	\$ 0.00		
TOTAL OF ABOVE CALCULATIONS				=	\$ 1,132.00	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must be filed. (Note 37 CFR 1.9, 1.27, 1.28)				\$		
SUBTOTAL				=	\$ 1,132.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	\$	
TOTAL NATIONAL FEE				=	\$ 1,132.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	\$	
TOTAL FEES ENCLOSED				=	\$ 1,132.00	
					Amount to be: refunded:	\$
					charged:	\$

a. ☒ A check in the amount of \$1,132.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0036. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit Under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. 1100 New York Avenue, NW, Suite 600 Washington, D.C. 20005-3934	<div style="font-size: 1.2em; font-family: cursive;">Eric K. Steffe</div> <div style="font-size: 0.8em;">SIGNATURE</div> <div style="font-size: 1.1em; font-weight: bold;">Eric K. Steffe</div> <div style="font-size: 0.8em;">NAME</div> <div style="font-size: 1.1em; font-weight: bold;">36.688</div> <div style="font-size: 0.8em;">REGISTRATION NUMBER</div>
---	---

09/646679

534 Rec'd PCT/PTO 20 SEP 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Wyatt *et al.*

Appl. No. To be assigned (U.S. National
Phase of PCT/GB99/00905)

Filed: Herewith

For: **Signal Transduction Protein
Involved in Plant Dehiscence**

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 0623.0890000/EKS/PSC

Second Preliminary Amendment

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In advance of prosecution please amend the application as follows:

In the Claims

Please amend the claims as follows:

3. Nucleic acid as claimed in claim 1 [or claim 2] which is naturally expressed in a dehiscence zone.

4. Nucleic acid as claimed in claim 1 encoding a protein wherein the protein:

- a) comprises the amino acid sequence shown in Figure 1 or;
- b) has one or more amino acid deletions, insertions or substitutions relative to a protein as defined in a) above, and has at least 40% amino acid sequence identity therewith; or

- c) a fragment of a protein as defined in a) or b) above which is at least 10 amino acids long.

5. Nucleic acid as claimed in [any one of claims 1 to 4] claim 1 which comprises the sequence set out in Figure 1 or a fragment thereof which is at least 30 bases long.

6. Nucleic acid, as claimed in [any one of claims 1 to 5] claim 1 in combination with one or more further nucleic acid sequence which is dehiscence-zone expressed.

7. Nucleic acid which is antisense to nucleic acid as claimed in [any one of claims 1 to 6] claim 1.

8. Nucleic acid as claimed in [any one of claims 1 to 7] claim 1 including a promoter or other regulatory sequence which controls expression of the nucleic acid.

9. Nucleic acid which is the naturally occurring promoter or other regulatory sequence which controls expression of nucleic acid as claimed in [any one claims 1 to 8] claim 1.

10. Nucleic acid as claimed in [any one of claims 1 to 9] claim 1 which is in the form of a vector.

11. A cell comprising nucleic acid as claimed in [any one of claims 1 to 10] claim 1.

13. A process for obtaining a cell [as claimed in claim 11 or claim 12] comprising introducing nucleic acid as claimed in [any one of claims 1 to 10] claim 1 into said cell.

14. A plant or a part thereof comprising a cell as claimed in [claim 11 or] claim 12.

15. Propagating material or a seed comprising a cell as claimed in [claim 11 or] claim 12.

16. A process for obtaining a plant or plant part [as claimed in claim 14 or claim 15] comprising obtaining a cell as claimed in claim 11 and growth thereof [or obtaining a plant, plant part, or propagating material as claimed in claim 14 or claim 15 and growth thereof].

18. A protein as claimed in claim 17 which:

- a) comprises the amino acid sequence shown in Figure 1 or;
- b) has one or more amino acid deletions, insertions or substitutions relative to a protein as defined in a) above, and has at least 40% amino acid sequence identity therewith; or
- c) a fragment of a protein as defined in a) or b) above which is at least 10 amino acids long.

19. A plant as claimed in claim 17 [or claim 18] which is isolated or recombinant.

21. A process [as claimed in claim 20] for regulating or controlling dehiscence in a plant or plant part which comprises obtaining a plant cell as claimed in [claim 21 or part of a plant as claimed in claim 14] claim 12 and deriving a plant therefrom.

22. A process for regulating or controlling dehiscence in a plant or plant part [as claimed in claim 20] which comprises obtaining propagating material or a seed as claimed in claim 15 and deriving a plant therefrom.

24. A process for controlling or regulating plant dehiscence comprising introducing the [Use of] nucleic acid as claimed in [any one of claims 1 to 10] claim 1 [in the control/regulation of plant dehiscence] into a cell, tissue, plant part thereof or propagating material and expressing said nucleic acid.

25. [Use of nucleic] Nucleic acid as claimed in [any one of claims 1 to 10 as] claim 4 which is a probe.

26. A process for producing a cell, tissue, plant part thereof or propagating material comprising introducing the [Use of] nucleic acid as claimed in [any one claims 1 to 10] claim 1 into a cell, tissue, plant part thereof or propagating material and causing growth of said cell, tissue, plant part thereof or propagating material [in the production of a cell, tissue, plant part thereof or propagating material].

29. [Use of a] A protein as claimed in [any one of claims 17 to 19] claim 18 which is [as] a probe.

Remarks

Claims 3-11, 13-16, 18-19, 21-22, 24-26, and 29 have been amended to delete multiple dependencies . The amendments do not add new matter and Applicants respectfully request that they be entered. Support for the amendments can be found throughout the specification (e.g. in the original claims). Upon entry of the forgoing amendment, claims 1-29 are pending in the application with claims 1, 17 and 27 being the independent claims.

It is not believed that extensions of time are required, beyond those that may otherwise be provided for in accompanying documents. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

Date: 9/20/00

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005
(202) 371-2600

09/646679

534 Rec'd PCT/PTO 20 SEP2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Wyatt *et al.*

Appl. No. To be assigned (U.S.
National Phase of
PCT/GB99/00905)

Filed: Herewith

For: **Signal Transduction Protein
Involved in Plant Dehiscence**

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 0623.0890000/EKS/PSC

Claim For Priority Under 35 U.S.C. § 119(a)-(d) In Utility Application

Commissioner for Patents
Washington, D.C. 20231

Sir:

Priority under 35 U.S.C. § 119(a)-(d) is hereby claimed to the following priority document(s), filed in a foreign country within twelve (12) months prior to the filing of the above-referenced United States utility patent application:

Country	Priority Document Appl. No.	Filing Date
Great Britain	GB9806113.8	20 March 1998

A certified copy of each listed priority document is submitted herewith. Prompt acknowledgment of this claim and submission is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

Date: 9/20/00
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

09/646679 0220

09/646679

534 Rec'd PCT/PTO 20 SEP 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Wyatt *et al.*

Appl. No. To be assigned
(U.S. Natl. Phase of PCT/GB99/00905)

Filed: Herewith

For: **Signal Protein Involved in Plant
Dehiscence**

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 0623.0890000/EKS/PSC

Preliminary Amendment and Submission of Sequence Listing

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In advance of prosecution, please amend the application as follows:

In the Specification:

Please insert the sequence listing at the end of the application.

On page 4, line 24, after "figure 1 ", please insert --(SEQ ID NO: 15)--.

On page 5, line 10, after "Figure 1 ", please insert --(SEQ ID NO: 15)--.

On page 6, line 25, after "figure 1 ", please insert --(SEQ ID NO: 15)--.

On page 8, line 17, after "figure 1 ", please insert --(SEQ ID NO: 14)--.

On page 8, line 19, after "Figure 1 ", please insert --(SEQ ID NO: 14)--.

On page 9, line 22, after "figure 1 ", please insert --(SEQ ID NO: 14)--.

On page 12, line 10, after "figure 1 ", please insert --(SEQ ID NO: 15)--.

On page 12, line 22, after "Figure 1 ", please insert --(SEQ ID NO: 15)--.

On page 14, line 12, after "Fig 5", please insert -- (SEQ ID NOs: 3, 5, and 6)--.

On page 14, line 12, after "Fig 9", please insert -- (SEQ ID NOs: 37 and 38)--.

On page 14, line 12, after "Fig 11", please insert -- (SEQ ID NOs: 7 and 8)--.

On page 18, line 15, after "Figure 15)", please insert --(SEQ ID NOs: 31 and 32)--.

On page 18, line 16, after "16)", please insert --(SEQ ID NOs: 33 and 34)--.

On page 18, line 16, after "(Figure 17)", please insert --(SEQ ID NOs: 35 and 36)--.

On page 19, line 9, after "Sac66", please insert --(SEQ ID NO: 31)--.

09/646679

On page 19, line 9, after "DZ15", please insert --(SEQ ID NO: 33)--.

On page 19, line 10, after "OSR(7)", please insert --(SEQ ID NO: 35)--.

On page 19, line 22, after "sites", please insert --(SEQ ID NOS: 14 and 15)--.

On page 20, line 7, after "DZ2B", please insert --(SEQ ID NO: 23)--.

On page 20, line 16, after "DZ2AT3 peptide", please insert --(SEQ ID NOS: 27 and 28)--.

On page 20, line 20, after "DZ2AT3", please insert --(SEQ ID NO: 29)--.

On page 21, line 2, after "Sac66", please insert --(SEQ ID NOS: 31 and 32)--.

On page 21, line 4, after "DZ15", please insert --(SEQ ID NOS: 33 and 34)--.

On page 21, line 6, after "OSR7", please insert --(SEQ ID NOS: 35 and 36)--.

On page 22, line 22, after "TGG-3'", please insert --(SEQ ID NO: 1)--.

On page 23, line 1, after "TGG-3'", please insert --(SEQ ID NO: 1)--.

On page 23, line 1, after "CGA A -3'", please insert --(SEQ ID NO: 2)--.

On page 23, line 14, after "TGG-3'", please insert --(SEQ ID NO: 1)--.

On page 23, line 14, after "CGA A -3'", please insert --(SEQ ID NO: 2)--.

On page 23, line 18, after "(Figure 1)", please insert -- (SEQ ID NO: 14)--.

On page 24, line 3, after "(Figure1)", please insert -- (SEQ ID NO: 14)--.

On page 25, line 15, after the first "(Figure 5)", please insert --(SEQ ID NO: 23)--.

On page 25, line 18, after "DZ2BFL", please insert -- (SEQ ID NO: 3)--.

On page 25, line 19, after "T7", please insert -- (SEQ ID NO: 4)--.

On page 26, line 13, after "DZ2BGENF", please insert -- (SEQ ID NO: 5)--.

On page 26, line 15, after "DZ2BGENR", please insert -- (SEQ ID NO: 6)--.

On page 27, line 7, after "Figure 9", please insert -- (SEQ ID NO: 27)--.

On page 27, line 28, after "(Figure 11)", please insert -- (SEQ ID NO: 29)--.

On page 28, line 1, after "ATDZ2F", please insert -- (SEQ ID NO: 7)--.

On page 28, line 2, after "ATDZ2R", please insert -- (SEQ ID NO: 8)--.

On page 30, line 5, after "DZ2FLA", please insert -- (SEQ ID NO: 9)--.

On page 30, line 6, after "DZ2RLA", please insert -- (SEQ ID NO: 10)--.

On page 31, line 15, after "Figure 15)", please insert -- (SEQ ID NOS: 31 and 32)--.

On page 31, line 16, after "16)", please insert -- (SEQ ID NOS: 33 and 34)--.

On page 31, line 16, after "Figure 17", please insert -- (SEQ ID NOs: 35 and 36)--.

On page 32, line 8, after "Figure 16)", please insert -- (SEQ ID NO: 33)--.

On page 32, line 15, after "T7", please insert -- (SEQ ID NO: 4)--.

On page 32, line 16, after "DZ15RL", please insert -- (SEQ ID NO: 11)--.

On page 32, line 25, after "F1", please insert -- (SEQ ID NO: 12)--.

On page 32, line 26, after "RI", please insert -- (SEQ ID NO: 13)--.

Remarks

The specification has been amended to direct the entry of this sequence listing after the claims of the above identified application and to provide sequence identifiers in all instances where the specification discusses the sequences. *See* 37 C.F.R. § 1.821(d).

In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter. In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

It is respectfully believed that this application is now in condition for examination. Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

Date: 9/20/00

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

P:\USERS\PChoi\0623\089\Seq List Submission Pleading.wpd
SKGF Rev. 12/30/99 mac

09/646679

-1-

SEQUENCE LISTING 534 Rec'd PCT/PTG 20 SEP 2000

<110> Wyatt, Paul
Roberts, Jeremy A.
Whitelaw, Catherine

<120> Signal Transduction Protein Involved in Plant Dehiscence

<130> 0623.0890000

<140> To Be Assigned

<141> Herewith

<150> GB9806113.8

<151> 1998-03-20

<160> 38

<170> PatentIn Ver. 2.0

<210> 1

<211> 14

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo dT primer 7

<400> 1

tttttttttt ttgg

14

<210> 2

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Arbitrary primer A

<400> 2

agccagcgaa

10

<210> 3

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer DZ2BFL

<400> 3

aaccaagtca gtagaagtg

19

<210> 4

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer T7

<400> 4

aatacgactc actatagg

18

<210> 5

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer DZ2BGENF

<400> 5

ggctctagac gaactgcgga gcaagg

26

<210> 6

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer DZ2BGENR

<400> 6

ctgccatggt cggttttttt tcttcgaac

29

<210> 7

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer ATDZ2F

<400> 7

cactagtagg gcacgcgtgg tcg

23

<210> 8

<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer ATDZ2R

<400> 8
tccatggtcg atttcttttc tctcaag 27

<210> 9
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer DZ2FLA

<400> 9
ggcgaattcc ggtgaggagg cagtaatc 28

<210> 10
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer DZ2RLA

<400> 10
ggcccatggc atacatacac acttagac 28

<210> 11
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer DZ15RL

<400> 11
aacagctgaa aacctcacga ag 22

<210> 12
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer F1

Prepared by: [illegible]

<400> 12
ggcccatggc tgccaagctt tgagtagc 28

<210> 13
<211> 27
<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer R1

<400> 13
ggcctgcagt gcctaggatc tggaagc 27

<210> 14
<211> 605
<212> DNA
<213> Brassica napus

<220>
<221> CDS
<222> (20) .. (427)

<400> 14
ggcacgagca gaatcgaag atg gca aca aaa tcc atg gga gat atc gag aaa 52
Met Ala Thr Lys Ser Met Gly Asp Ile Glu Lys
1 5 10

ata aag aag aaa cta aac gtg ttg atc gtc gat gat gat cca cta aac 100
Ile Lys Lys Lys Leu Asn Val Leu Ile Val Asp Asp Asp Pro Leu Asn
15 20 25

ctt ata att cat gag aag atc atc aaa gcg att ggg ggt att tca cag 148
Leu Ile Ile His Glu Lys Ile Ile Lys Ala Ile Gly Gly Ile Ser Gln
30 35 40

aca gcg aat aac ggt gag gag gca gta atc atc cac cgt gac ggc ggc 196
Thr Ala Asn Asn Gly Glu Glu Ala Val Ile Ile His Arg Asp Gly Gly
45 50 55

tca tct ttt gac ctt atc cta atg gat aaa gaa atg ccc gag agg gat 244
Ser Ser Phe Asp Leu Ile Leu Met Asp Lys Glu Met Pro Glu Arg Asp
60 65 70 75

ggg gtt tcg aca act aag aag cta aga gaa atg gaa gtg aag tca atg 292
Gly Val Ser Thr Thr Lys Lys Leu Arg Glu Met Glu Val Lys Ser Met
80 85 90

att gtt ggg gtg act tca ctg gct gac aat gaa gag gag cgc agg gct 340
Ile Val Gly Val Thr Ser Leu Ala Asp Asn Glu Glu Glu Arg Arg Ala
95 100 105

Accession: Z53960

ttc atg gaa gct gga ctt aac cat tgc ttg gca aaa ccg tta acc aag 388
Phe Met Glu Ala Gly Leu Asn His Cys Leu Ala Lys Pro Leu Thr Lys
110 115 120

gac aag atc atc cct ctc att aac caa ctc atg gat gct tgatggatat 437
Asp Lys Ile Ile Pro Leu Ile Asn Gln Leu Met Asp Ala
125 130 135

atatatttata ttatggaaac acacataata acgtctaagt gtgtatgtat gcatagatac 497

ttgcatgtgt gtgtttttaga atttaggggtt ctttatcgtc cgtgatatat aatcatgtaa 557

gttggttgctt taagcttata aaatatttaa ataagggttt cctctacc 605

<210> 15

<211> 136

<212> PRT

<213> Brassica napus

<400> 15

Met Ala Thr Lys Ser Met Gly Asp Ile Glu Lys Ile Lys Lys Lys Leu
1 5 10 15

Asn Val Leu Ile Val Asp Asp Asp Pro Leu Asn Leu Ile Ile His Glu
20 25 30

Lys Ile Ile Lys Ala Ile Gly Gly Ile Ser Gln Thr Ala Asn Asn Gly
35 40 45

Glu Glu Ala Val Ile Ile His Arg Asp Gly Gly Ser Ser Phe Asp Leu
50 55 60

Ile Leu Met Asp Lys Glu Met Pro Glu Arg Asp Gly Val Ser Thr Thr
65 70 75 80

Lys Lys Leu Arg Glu Met Glu Val Lys Ser Met Ile Val Gly Val Thr
85 90 95

Ser Leu Ala Asp Asn Glu Glu Glu Arg Arg Ala Phe Met Glu Ala Gly
100 105 110

Leu Asn His Cys Leu Ala Lys Pro Leu Thr Lys Asp Lys Ile Ile Pro
115 120 125

Leu Ile Asn Gln Leu Met Asp Ala
130 135

<210> 16

<211> 136

<212> PRT

<213> Brassica napus

<400> 16

12345678910111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970717273747576777879808182838485868788899091929394959697989910010110210310410510610710810911011111211311411511611711811912012112212312412512612712812913013113213313413513613713813914014114214314414514614714814915015115215315415515615715815916016116216316416516616716816917017117217317417517617717817918018118218318418518618718818919019119219319419519619719819920020120220320420520620720820921021121221321421521621721821922022122222322422522622722822923023123223323423523623723823924024124224324424524624724824925025125225325425525625725825926026126226326426526626726826927027127227327427527627727827928028128228328428528628728828929029129229329429529629729829930030130230330430530630730830931031131231331431531631731831932032132232332432532632732832933033133233333433533633733833934034134234334434534634734834935035135235335435535635735835936036136236336436536636736836937037137237337437537637737837938038138238338438538638738838939039139239339439539639739839940040140240340440540640740840941041141241341441541641741841942042142242342442542642742842943043143243343443543643743843944044144244344444544644744844945045145245345445545645745845946046146246346446546646746846947047147247347447547647747847948048148248348448548648748848949049149249349449549649749849950050150250350450550650750850951051151251351451551651751851952052152252352452552652752852953053153253353453553653753853954054154254354454554654754854955055155255355455555655755855956056156256356456556656756856957057157257357457557657757857958058158258358458558658758858959059159259359459559659759859960060160260360460560660760860961061161261361461561661761861962062162262362462562662762862963063163263363463563663763863964064164264364464564664764864965065165265365465565665765865966066166266366466566666766866967067167267367467567667767867968068168268368468568668768868969069169269369469569669769869970070170270370470570670770870971071171271371471571671771871972072172272372472572672772872973073173273373473573673773873974074174274374474574674774874975075175275375475575675775875976076176276376476576676776876977077177277377477577677777877978078178278378478578678778878979079179279379479579679779879980080180280380480580680780880981081181281381481581681781881982082182282382482582682782882983083183283383483583683783883984084184284384484584684784884985085185285385485585685785885986086186286386486586686786886987087187287387487587687787887988088188288388488588688788888989089189289389489589689789889990090190290390490590690790890991091191291391491591691791891992092192292392492592692792892993093193293393493593693793893994094194294394494594694794894995095195295395495595695795895996096196296396496596696796896997097197297397497597697797897998098198298398498598698798898999099199299399499599699799899910001001100210031004100510061007100810091010101110121013101410151016101710181019102010211022102310241025102610271028102910301031103210331034103510361037103810391040104110421043104410451046104710481049105010511052105310541055105610571058105910601061106210631064106510661067106810691070107110721073107410751076107710781079108010811082108310841085108610871088108910901091109210931094109510961097109810991100110111021103110411051106110711081109111011111112111311141115111611171118111911201121112211231124112511261127112811291130113111321133113411351136113711381139114011411142114311441145114611471148114911501151115211531154115511561157115811591160116111621163116411651166116711681169117011711172117311741175117611771178117911801181118211831184118511861187118811891190119111921193119411951196119711981199120012011202120312041205120612071208120912101211121212131214121512161217121812191220122112221223122412251226122712281229123012311232123312341235123612371238123912401241124212431244124512461247124812491250125112521253125412551256125712581259126012611262126312641265126612671268126912701271127212731274127512761277127812791280128112821283128412851286128712881289129012911292129312941295129612971298129913001301130213031304130513061307130813091310131113121313131413151316131713181319132013211322132313241325132613271328132913301331133213331334133513361337133813391340134113421343134413451346134713481349135013511352135313541355135613571358135913601361136213631364136513661367136813691370137113721373137413751376137713781379138013811382138313841385138613871388138913901391139213931394139513961397139813991400140114021403140414051406140714081409141014111412141314141415141614171418141914201421142214231424142514261427142814291430143114321433143414351436143714381439144014411442144314441445144614471448144914501451145214531454145514561457145814591460146114621463146414651466146714681469147014711472147314741475147614771478147914801481148214831484148514861487148814891490149114921493149414951496149714981499150015011502150315041505150615071508150915101511151215131514151515161517151815191520152115221523152415251526152715281529153015311532153315341535153615371538153915401541154215431544154515461547154815491550155115521553155415551556155715581559156015611562156315641565156615671568156915701571157215731574157515761577157815791580158115821583158415851586158715881589159015911592159315941595159615971598159916001601160216031604160516061607160816091610161116121613161416151616161716181619162016211622162316241625162616271628162916301631163216331634163516361637163816391640164116421643164416451646164716481649165016511652165316541655165616571658165916601661166216631664166516661667166816691670167116721673167416751676167716781679168016811682168316841685168616871688168916901691169216931694169516961697169816991700170117021703170417051706170717081709171017111712171317141715171617171718171917201721172217231724172517261727172817291730173117321733173417351736173717381739174017411742174317441745174617471748174917501751175217531754175517561757175817591760176117621763176417651766176717681769177017711772177317741775177617771778177917801781178217831784178517861787178817891790179117921793179417951796179717981799180018011802180318041805180618071808180918101811181218131814181518161817181818191820182118221823182418251826182718281829183018311832183318341835183618371838183918401841184218431844184518461847184818491850185118521853185418551856185718581859186018611862186318641865186618671868186918701871187218731874187518761877187818791880188118821883188418851886188718881889189018911892189318941895189618971898189919001901190219031904190519061907190819091910191119121913191419151916191719181919192019211922192319241925192619271928192919301931193219331934193519361937193819391940194119421943194419451946194719481949195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030203120322033203420352036203720382039204020412042204320442045204620472048204920502051205220532054205520562057205820592060206120622063206420652066206720682069207020712072207320742075207620772078207920802081208220832084208520862087208820892090209120922093209420952096209720982099210021012102210321042105210621072108210921102111211221132114211521162117211821192120212121222123212421252126212721282129213021312132213321342135213621372138213921402141214221432144214521462147214821492150215121522153215421552156215721582159216021612162216321642165216621672168216921702171217221732174217521762177217821792180218121822183218421852186218721882189219021912192219321942195219621972198219922002201220222032204220522062207220822092210221122122213221422152216221722182219222022212222222322242225222622272228222922302231223222332234223522362237223822392240224122422243224422452246224722482249225022512252225322542255225622572258225922602261226222632264226522662267226822692270227122722273227422752276227722782279228022812282228322842285228622872288228922902291229222932294229522962297229822992300230123022303230423052306230723082309231023112312231323142315231623172318231923202321232223232324232523262327232823292330233123322333233423352336233723382339234023412342234323442345234623472348234923502351235223532354235523562357235823592360236123622363236423652366236723682369237023712372237323742375237623772378237923802381238223832384238523862387238823892390239123922393239423952396239723982399240024012402240324042405240624072408240924102411241224132414241524162417241824192420242124222423242424252426242724282429243024312432243324342435243624372438243924402441244224432444244524462447244824492450245124522453245424552456245724582459246024612462246324642465246624672468246924702471247224732474247524762477247824792480248124822483248424852486248724882489249024912492249324942495249624972498249925002501250225032504250525062507250825092510251125122513251425152516251725182519252025212522252325242525252625272528252925302531253225332534253525362537253825392540254125422543254425452546254725482549255025512552255325542555255625572558255925602561256225632564256525662567256825692570257125722573257425752576257725782579258025812582258325842585258625872588258925902591259225932594259525962597259825992600260126022603260426052606260726082609261026112612261326142615261626172618261926202621262226232624262526262627262826292630263126322633263426352636263726382639264026412642264326442645264626472648264926502651265226532654265526562657265826592660266126622663266426652666266726682669267026712672267326742675267626772678267926802681268226832684268526862687268826892690269126922693269426952696269726982699270027012702270327042705270627072708270927102711271227132714271527162717271827192720272127222723272427252726272727282729273027312732273327342735273627372738273927402741274227432744274527462747274827492750275127522753275427552756275727582759276027612762276327642765276627672768276927702771277227732774277527762777277827792780278127822783278427852786278727882789279027912792279327942795279627972798279928002801280228032804280528062807280828092810281128122813281428152816281728182819282028212822282328242825282628272828282928302831283228332834283528362837283828392840284128422843284428452846284728482849285028512852285328542855285628572858285928602861286228632864286528662867286828692870287128722873287428752876287728782879288028812882288328842885288628872888288928902891289228932894289528962897289828992900290129022903290429052906290729082909291029112912291329142915291629172918291929202921292229232924292529262927292829292930293129322933293429352936293729382939294029412942294329442945294629472948294929502951295229532954295529562957295829592960296129622963296429652966296729682969297029712972297329742975297629772978297929802981298229832984298529862

Ile Gly Ala Asp Asp Tyr Ile Pro Lys Pro Phe Asn Pro Arg Glu Leu
100 105 110

Ser Lys Thr Pro Asp Val Leu Leu Ser Asp Ile Arg Met Pro Gly Met
50 55 60

Asp Gly Leu Ala Leu Leu Lys Gln Ile Lys Gln Arg His Pro Met Leu
65 70 75 80

Pro Val Ile Ile Met Thr Ala Asn Thr Arg Cys His Ser Asp Leu Asp
85 90 95

Ala Ala Val Ser Ala Tyr Gln Gln Gly Ala Phe Asp Tyr Leu Pro Lys
100 105 110

Pro Phe Asp Ile Asp Glu Ala Val Ala Leu Val Glu Arg Ala Ile Ser
115 120 125

His Tyr Gln Glu Gln Gln Gln Pro Arg Asn Ile Glu Val Asn Gly Pro
130 135 140

<210> 20

<211> 124

<212> PRT

<213> Bacillus subtilis

<400> 20

Met Met Asn Glu Lys Ile Leu Ile Val Asp Asp Gln Tyr Gly Ile Arg
1 5 10 15

Ile Leu Leu Asn Glu Val Phe Asn Lys Glu Gly Tyr Gln Thr Phe Gln
20 25 30

Ala Ala Asn Gly Leu Gln Ala Leu Asp Ile Val Thr Lys Glu Arg Pro
35 40 45

Asp Leu Val Leu Leu Asp Met Lys Ile Pro Gly Met Asp Gly Ile Glu
50 55 60

Ile Leu Lys Arg Met Lys Val Ile Asp Glu Asn Ile Arg Val Ile Ile
65 70 75 80

Met Thr Ala Tyr Gly Glu Leu Asp Met Ile Gln Glu Ser Lys Glu Leu
85 90 95

Gly Ala Leu Thr His Phe Ala Lys Pro Phe Asp Ile Asp Glu Ile Arg
100 105 110

Asp Ala Val Lys Lys Tyr Leu Pro Leu Lys Ser Asn
115 120

<210> 21

<211> 129

<212> PRT

<213> Escherichia coli

<400> 21

Met Ala Asp Lys Glu Leu Lys Phe Leu Val Val Asp Asp Phe Ser Thr

1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556575859606162636465666768697071727374757677787980818283848586878889909192939495969798991001011021031041051061071081091101111121131141151161171181191201211221231241251261271281291301311321331341351361371381391401411421431441451461471481491501511521531541551561571581591601611621631641651661671681691701711721731741751761771781791801811821831841851861871881891901911921931941951961971981992002012022032042052062072082092102112122132142152162172182192202212222232242252262272282292302312322332342352362372382392402412422432442452462472482492502512522532542552562572582592602612622632642652662672682692702712722732742752762772782792802812822832842852862872882892902912922932942952962972982993003013023033043053063073083093103113123133143153163173183193203213223233243253263273283293303313323333343353363373383393403413423433443453463473483493503513523533543553563573583593603613623633643653663673683693703713723733743753763773783793803813823833843853863873883893903913923933943953963973983994004014024034044054064074084094104114124134144154164174184194204214224234244254264274284294304314324334344354364374384394404414424434444454464474484494504514524534544554564574584594604614624634644654664674684694704714724734744754764774784794804814824834844854864874884894904914924934944954964974984995005015025035045055065075085095105115125135145155165175185195205215225235245255265275285295305315325335345355365375385395405415425435445455465475485495505515525535545555565575585595605615625635645655665675685695705715725735745755765775785795805815825835845855865875885895905915925935945955965975985996006016026036046056066076086096106116126136146156166176186196206216226236246256266276286296306316326336346356366376386396406416426436446456466476486496506516526536546556566576586596606616626636646656666676686696706716726736746756766776786796806816826836846856866876886896906916926936946956966976986997007017027037047057067077087097107117127137147157167177187197207217227237247257267277287297307317327337347357367377387397407417427437447457467477487497507517527537547557567577587597607617627637647657667677687697707717727737747757767777787797807817827837847857867877887897907917927937947957967977987998008018028038048058068078088098108118128138148158168178188198208218228238248258268278288298308318328338348358368378388398408418428438448458468478488498508518528538548558568578588598608618628638648658668678688698708718728738748758768778788798808818828838848858868878888898908918928938948958968978988999009019029039049059069079089099109119129139149159169179189199209219229239249259269279289299309319329339349359369379389399409419429439449459469479489499509519529539549559569579589599609619629639649659669679689699709719729739749759769779789799809819829839849859869879889899909919929939949959969979989991000100110021003100410051006100710081009101010111012101310141015101610171018101910201021102210231024102510261027102810291030103110321033103410351036103710381039104010411042104310441045104610471048104910501051105210531054105510561057105810591060106110621063106410651066106710681069107010711072107310741075107610771078107910801081108210831084108510861087108810891090109110921093109410951096109710981099110011011102110311041105110611071108110911101111111211131114111511161117111811191120112111221123112411251126112711281129113011311132113311341135113611371138113911401141114211431144114511461147114811491150115111521153115411551156115711581159116011611162116311641165116611671168116911701171117211731174117511761177117811791180118111821183118411851186118711881189119011911192119311941195119611971198119912001201120212031204120512061207120812091210121112121213121412151216121712181219122012211222122312241225122612271228122912301231123212331234123512361237123812391240124112421243124412451246124712481249125012511252125312541255125612571258125912601261126212631264126512661267126812691270127112721273127412751276127712781279128012811282128312841285128612871288128912901291129212931294129512961297129812991300130113021303130413051306130713081309131013111312131313141315131613171318131913201321132213231324132513261327132813291330133113321333133413351336133713381339134013411342134313441345134613471348134913501351135213531354135513561357135813591360136113621363136413651366136713681369137013711372137313741375137613771378137913801381138213831384138513861387138813891390139113921393139413951396139713981399140014011402140314041405140614071408140914101411141214131414141514161417141814191420142114221423142414251426142714281429143014311432143314341435143614371438143914401441144214431444144514461447144814491450145114521453145414551456145714581459146014611462146314641465146614671468146914701471147214731474147514761477147814791480148114821483148414851486148714881489149014911492149314941495149614971498149915001501150215031504150515061507150815091510151115121513151415151516151715181519152015211522152315241525152615271528152915301531153215331534153515361537153815391540154115421543154415451546154715481549155015511552155315541555155615571558155915601561156215631564156515661567156815691570157115721573157415751576157715781579158015811582158315841585158615871588158915901591159215931594159515961597159815991600160116021603160416051606160716081609161016111612161316141615161616171618161916201621162216231624162516261627162816291630163116321633163416351636163716381639164016411642164316441645164616471648164916501651165216531654165516561657165816591660166116621663166416651666166716681669167016711672167316741675167616771678167916801681168216831684168516861687168816891690169116921693169416951696169716981699170017011702170317041705170617071708170917101711171217131714171517161717171817191720172117221723172417251726172717281729173017311732173317341735173617371738173917401741174217431744174517461747174817491750175117521753175417551756175717581759176017611762176317641765176617671768176917701771177217731774177517761777177817791780178117821783178417851786178717881789179017911792179317941795179617971798179918001801180218031804180518061807180818091810181118121813181418151816181718181819182018211822182318241825182618271828182918301831183218331834183518361837183818391840184118421843184418451846184718481849185018511852185318541855185618571858185918601861186218631864186518661867186818691870187118721873187418751876187718781879188018811882188318841885188618871888188918901891189218931894189518961897189818991900190119021903190419051906190719081909191019111912191319141915191619171918191919201921192219231924192519261927192819291930193119321933193419351936193719381939194019411942194319441945194619471948194919501951195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032203320342035203620372038203920402041204220432044204520462047204820492050205120522053205420552056205720582059206020612062206320642065206620672068206920702071207220732074207520762077207820792080208120822083208420852086208720882089209020912092209320942095209620972098209921002101210221032104210521062107210821092110211121122113211421152116211721182119212021212122212321242125212621272128212921302131213221332134213521362137213821392140214121422143214421452146214721482149215021512152215321542155215621572158215921602161216221632164216521662167216821692170217121722173217421752176217721782179218021812182218321842185218621872188218921902191219221932194219521962197219821992200220122022203220422052206220722082209221022112212221322142215221622172218221922202221222222232224222522262227222822292230223122322233223422352236223722382239224022412242224322442245224622472248224922502251225222532254225522562257225822592260226122622263226422652266226722682269227022712272227322742275227622772278227922802281228222832284228522862287228822892290229122922293229422952296229722982299230023012302230323042305230623072308230923102311231223132314231523162317231823192320232123222323232423252326232723282329233023312332233323342335233623372338233923402341234223432344234523462347234823492350235123522353235423552356235723582359236023612362236323642365236623672368236923702371237223732374237523762377237823792380238123822383238423852386238723882389239023912392239323942395239623972398239924002401240224032404240524062407240824092410241124122413241424152416241724182419242024212422242324242425242624272428242924302431243224332434243524362437243824392440244124422443244424452446244724482449245024512452245324542455245624572458245924602461246224632464246524662467246824692470247124722473247424752476247724782479248024812482248324842485248624872488248924902491249224932494249524962497249824992500250125022503250425052506250725082509251025112512251325142515251625172518251925202521252225232524252525262527252825292530253125322533253425352536253725382539254025412542254325442545254625472548254925502551255225532554255525562557255825592560256125622563256425652566256725682569257025712572257325742575257625772578257925802581258225832584258525862587258825892590259125922593259425952596259725982599260026012602260326042605260626072608260926102611261226132614261526162617261826192620262126222623262426252626262726282629263026312632263326342635263626372638263926402641264226432644264526462647264826492650265126522653265426552656265726582659266026612662266326642665266626672668266926702671267226732674267526762677267826792680268126822683268426852686268726882689269026912692269326942695269626972698269927002701270227032704270527062707270827092710271127122713271427152716271727182719272027212722272327242725272627272728272927302731273227332734273527362737273827392740274127422743274427452746274727482749275027512752275327542755275627572758275927602761276227632764276527662767276827692770277127722773277427752776277727782779278027812782278327842785278627872788278927902791279227932794279527962797279827992800280128022803280428052806280728082809281028112812281328142815281628172818281928202821282228232824282528262827282828292830283128322833283428352836283728382839284028412842284328442845284628472848284928502851285228532854285528562857285828592860286128622863286428652866286728682869287028712872287328742875287628772878287928802881288228832884288528862887288828892890289128922893289428952896289728982899290029012902290329042905290629072908290929102911291229132914291529162917291829192920292129222923292429252926292729282929293029312932293329342935293629372938293929402941294229432944294529462947294829492950295129522953295429552956295729582959296029612962296329642965296629672968296929702971297229732974297529762977297829792980298129822983298429852986298729882989299029912992299329942995299629972998299930003

1	5	10	15
Met Arg Arg Ile Val Arg Asn Leu Leu Lys Glu Leu Gly Phe Asn Asn	20	25	30
Val Glu Glu Ala Glu Asp Gly Val Asp Ala Leu Asn Lys Leu Gln Ala	35	40	45
Gly Gly Tyr Gly Phe Val Ile Ser Asp Trp Asn Met Pro Asn Met Asp	50	55	60
Gly Leu Glu Leu Leu Lys Thr Ile Arg Ala Asp Gly Ala Met Ser Ala	65	70	75
Leu Pro Val Leu Met Val Thr Ala Glu Ala Lys Lys Glu Asn Ile Ile	85	90	95
Ala Ala Ala Gln Ala Gly Ala Ser Gly Tyr Val Val Lys Pro Phe Thr	100	105	110
Pro Ala Thr Leu Glu Glu Lys Leu Asn Lys Ile Phe Glu Lys Leu Gly	115	120	125

Met

<210> 22
 <211> 111
 <212> PRT
 <213> Arabidopsis thaliana

<220>
 <221> Unsure
 <222> 67
 <223> Xaa= any amino acid

<400> 22
Leu Lys Val Leu Val Met Asp Glu Asn Gly Val Ser Arg Met Val Thr
1 5 10 15
Lys Gly Leu Leu Val His Leu Gly Cys Glu Val Thr Thr Val Ser Ser
20 25 30
Asn Glu Glu Cys Leu Arg Val Val Ser His Glu His Lys Val Val Phe
35 40 45
Met Asp Val Cys Met Pro Gly Val Glu Asn Tyr Gln Ile Ala Leu Arg
50 55 60
Ile His Xaa Pro Leu Leu Val Ala Leu Ser Gly Asn Thr Asp Lys Ser
65 70 75 80
Thr Lys Glu Lys Cys Met Ser Phe Gly Leu Asp Gly Val Leu Leu Lys
85 90 95

Pro Val Ser Leu Asp Asn Ile Arg Asp Val Leu Ser Asp Leu Leu
100 105 110

<210> 23
<211> 1716
<212> DNA
<213> Brassica napus

<220>
<221> CDS
<222> (1516)..(1716)

<220>
<221> Unsure
<222> 48
<223> n= any nucleotide

<220>
<221> Unsure
<222> 56
<223> n= any nucleotide

<220>
<221> Unsure
<222> 57
<223> n= any nucleotide

<220>
<221> Unsure
<222> 62
<223> n= any nucleotide

<220>
<221> Unsure
<222> 72
<223> n= any nucleotide

<220>
<221> Unsure
<222> 76
<223> n= any nucleotide

<220>
<221> Unsure
<222> 80
<223> n= any nucleotide

<220>
<221> Unsure
<222> 103
<223> n= any nucleotide

<220>
<221> Unsure

100 105 110

```
<400> 23
tatataaata cggtttaaca gatatgttct gggtataaat gtaattcnat gtgccnntca 60
antttttattn tnatnngttn tactagggac attagtttta acntttttata tatcatgtaa 120
caaaaaaaaaa aaaaacnttt tatatntcaa ctatgagcaa ttattcttat agtgttttct 180
ttttccagaa atttgacgac aacctaaacta aaacaattta atttgacgtt agttaagtaa 240
tttatataga tggataaatt gagcaagcac attacgaact gcggatcaag gagagtcaca 300
atttaattct tacgttatac acaaaattat ctaaatacta tatatatata cagctgcatg 360
ctacgataat gatcaaatgt ttatgtactt ttcagcgaaa attcttgtcg ccatacatta 420
ctgtgttaat gaatcattaa atatgtgaag gaggaaaaga gtacaaaagg agttttgttg 480
```

aggcatttcg cagacactga aatgtgaata ataataaagg aattgccgaa ttgatttcta 540
 gttggtgaag tgggtgaaaa ttgtatgtcc attgcttata aactataaaa tataatatnt 600
 tnatattatc actntggaca ttagtnngat agaccctagc taaaattttt aaaaattata 660
 cattcatttt ctnaagtacc aaacttaatt atcacaatcg gataaaattg ttttaagaaac 720
 cattacaaac tcagcttgtg gactctgaga gaaactaaga gctagacata cggtagtag 780
 ttagccgca ttttttatgc ttaatttgc ttagcatgac ttctatgctc cttgatgata 840
 tttattttta taccctagga catatggatt tgataaagat cttatcaacc tttcaacaag 900
 accattagct caacaaacaa aatactgaaa gtatataatc ttggttacag aattcttatg 960
 ccaaaaatat cataatatat atagaattcg gttatgatta agatgaatta ttttaattaat 1020
 atatttttca cttttgtttt cttatgtatt cttagtattt gttcaccata ttgaccgatt 1080
 ggtgtcatat tagtttggtg agacaactca gttgcaacga tgcagattac atttcaggaa 1140
 gattcatgta agaaagatat ttcgcttctg ggtgtgaaaa tatgcctctt tcactttttt 1200
 tcaactataa atttcgatcg atgtatctac gttcttaaca caattcaca tcttcttttag 1260
 aatccaaaat tgtaagccgc tttctaactc ctttctcagt atacatatgt aatatgtatg 1320
 catatattat tattcataat acaaacacga acccatgcat gcaagaagat agttacacgc 1380
 tcataacaaa cacaaaaaaaa catacgcatg cattagaaca cttgtatggt aatttccata 1440
 atgttttgca taaacattct tcgttttaat tagcttcttt ttgtgtgaag attgttcgaa 1500
 gaaaaaaaaac cgaag atg gca aca acg tca aca tcc acg gga gat atc aag 1551
 Met Ala Thr Thr Ser Thr Ser Thr Gly Asp Ile Lys
 1 5 10
 aaa acc aag tca gta gaa gtg aag aag aaa ctt aac gtg ttg atc gtt 1599
 Lys Thr Lys Ser Val Glu Val Lys Lys Lys Leu Asn Val Leu Ile Val
 15 20 25
 gat gat gat aca gta att cgt aaa ctt cac gag aat atc atc aaa tcg 1647
 Asp Asp Asp Thr Val Ile Arg Lys Leu His Glu Asn Ile Ile Lys Ser
 30 35 40
 atc ggt gga att tca cag acg gct aag aac ggt gag gag gca gtg aac 1695
 Ile Gly Gly Ile Ser Gln Thr Ala Lys Asn Gly Glu Glu Ala Val Asn
 45 50 55 60
 atc cac cgc gac ggc aat gca 1716
 Ile His Arg Asp Gly Asn Ala
 65

<210> 24
 <211> 67
 <212> PRT
 <213> Brassica napus

<400> 24
 Met Ala Thr Thr Ser Thr Ser Thr Gly Asp Ile Lys Lys Thr Lys Ser
 1 5 10 15
 Val Glu Val Lys Lys Lys Leu Asn Val Leu Ile Val Asp Asp Asp Thr
 20 25 30
 Val Ile Arg Lys Leu His Glu Asn Ile Ile Lys Ser Ile Gly Gly Ile
 35 40 45
 Ser Gln Thr Ala Lys Asn Gly Glu Glu Ala Val Asn Ile His Arg Asp
 50 55 60
 Gly Asn Ala
 65

<210> 25
 <211> 576
 <212> DNA
 <213> Brassica napus

<220>
 <221> Unsure
 <222> 6
 <223> n= any nucleotide

<220>
 <221> Unsure
 <222> 518
 <223> n= any nucleotide

<400> 25
 tcgtcnatga tgatcctgta atacgtaaac ttcacgagat tatcatcaaa tcaatcggtg 60
 gaatttcaca gacagctaag aacgggtgagg aggcagtga catccaccgc gacggcaatg 120
 catcttttga ccttatccta atggataaag aaatgcccg gagggatgga ctttcggcaa 180
 ctaagaagct aagagaaatg aaagtgacgt ctatgattat tggggtgacg aactggtg 240
 acaatgaaga ggaacgtaag gctttcatgg aagctggact taaccattgc ttggcaaaac 300
 ccttaagcaa agccaagatc ctccctctca tcaacaatct catggatgct tgatggatgg 360
 atgaattgtc gccactacat atctacatta tacaatatg aaaaacacat ataataacgt 420
 catacacctg tgtgtgtatg catagatatc tatccgcatg tgtgttttta gggttgttat 480
 gtttgatttt tattgtgcgt ggogtgatat acaatcangt nagtcgttac ttttggttta 540

6257332

taaaataatg aataagattt gttaaaaata aaaaaa

576

<210> 26
<211> 116
<212> PRT
<213> Brassica napus

<220>
<221> Unsure
<222> 2
<223> Xaa= any amino acid

<400> 26
Val Xaa Asp Asp Pro Val Ile Arg Lys Leu His Glu Ile Ile Ile Lys
1 5 10 15
Ser Ile Gly Gly Ile Ser Gln Thr Ala Lys Asn Gly Glu Glu Ala Val
20 25 30
Asn Ile His Arg Asp Gly Asn Ala Ser Phe Asp Leu Ile Leu Met Asp
35 40 45
Lys Glu Met Pro Glu Arg Asp Gly Leu Ser Ala Thr Lys Lys Leu Arg
50 55 60
Glu Met Lys Val Thr Ser Met Ile Ile Gly Val Thr Thr Leu Ala Asp
65 70 75 80
Asn Glu Glu Glu Arg Lys Ala Phe Met Glu Ala Gly Leu Asn His Cys
85 90 95
Leu Ala Lys Pro Leu Ser Lys Ala Lys Ile Leu Pro Leu Ile Asn Asn
100 105 110
Leu Met Asp Ala
115

<210> 27
<211> 818
<212> DNA
<213> Arabidopsis thaliana

<220>
<221> CDS
<222> (180)..(605)

<220>
<221> Unsure
<222> 350
<223> n= any nucleotide

<220>

102220 "66337360

<221> Unsure

<222> 57

<223> Xaa= any amino acid

<400> 27

```

atatatgtga tacagataca tctatataca aattaaacac gaaaccatac atgcacggtg 60

tgatcacaca cgcacacaca tagaaacata aacacgcaat aattttctata cagttttaatt 120

tcattttttaa cttacttctt tttttttggt gaagattctt gagagaaaag aaatcgaag 179

atg gca aca aaa tcc acc gga ggt acc gag aaa acc aag tcg ata gaa 227
Met Ala Thr Lys Ser Thr Gly Gly Thr Glu Lys Thr Lys Ser Ile Glu
  1             5             10             15

gtg aag aag aaa cta atc aac gtg ttg atc gtc gat gat gat cca tta 275
Val Lys Lys Lys Leu Ile Asn Val Leu Ile Val Asp Asp Asp Pro Leu
          20             25             30

aac cgt aga ctc cac gag atg atc atc aaa acg atc gga gga att tct 323
Asn Arg Arg Leu His Glu Met Ile Ile Lys Thr Ile Gly Gly Ile Ser
          35             40             45

cag act gca aag aat ggc gaa gag gcn gtg atc ctc cac cgt gac ggc 371
Gln Thr Ala Lys Asn Gly Glu Glu Xaa Val Ile Leu His Arg Asp Gly
          50             55             60

gaa gca tct ttc gac ctt att cta atg gat aag gaa atg cct gag agg 419
Glu Ala Ser Phe Asp Leu Ile Leu Met Asp Lys Glu Met Pro Glu Arg
          65             70             75             80

gat gga gtt tcg aca att aag ang cta aga gaa atg aaa ggg acg tca 467
Asp Gly Val Ser Thr Ile Lys Xaa Leu Arg Glu Met Lys Gly Thr Ser
          85             90             95

atg atc gtt ggg gta acg tca gta gct gac caa gaa gaa gag cgt aag 515
Met Ile Val Gly Val Thr Ser Val Ala Asp Gln Glu Glu Glu Arg Lys
          100            105            110

gct ttt atg gaa gct ggg ctc aac cat tgc ttg gaa aaa ccc tta acc 563
Ala Phe Met Glu Ala Gly Leu Asn His Cys Leu Glu Lys Pro Leu Thr
          115            120            125

aag gcc aag atc ttc ccg ctc att agc cac ctc ttc gat gct 605
Lys Ala Lys Ile Phe Pro Leu Ile Ser His Leu Phe Asp Ala
          130            135            140

tgatggatga aggetcatta atgtatctat attttcaatc atgaaatcac ctacacgtgt 665

at ttgacaca aaaatctgca tttgttgtga tatagggttt ctcatatcta tgtttgattt 725

at tttcttat cgtccgaggt aaaatcatgc aagtcatttc ttttggctaa taaaatatta 785

aaataaggtt ttctcaaaaa aaaaaaaaaa aaa 818

```

<210> 28
 <211> 142
 <212> PRT
 <213> Arabidopsis thaliana

<220>
 <221> Unsure
 <222> 57
 <223> Xaa= any amino acid

<220>
 <221> Unsure
 <222> 88
 <223> Xaa= any amino acid

<400> 28
 Met Ala Thr Lys Ser Thr Gly Gly Thr Glu Lys Thr Lys Ser Ile Glu
 1 5 10 15
 Val Lys Lys Lys Leu Ile Asn Val Leu Ile Val Asp Asp Asp Pro Leu
 20 25 30
 Asn Arg Arg Leu His Glu Met Ile Ile Lys Thr Ile Gly Gly Ile Ser
 35 40 45
 Gln Thr Ala Lys Asn Gly Glu Glu Xaa Val Ile Leu His Arg Asp Gly
 50 55 60
 Glu Ala Ser Phe Asp Leu Ile Leu Met Asp Lys Glu Met Pro Glu Arg
 65 70 75 80
 Asp Gly Val Ser Thr Ile Lys Xaa Leu Arg Glu Met Lys Gly Thr Ser
 85 90 95
 Met Ile Val Gly Val Thr Ser Val Ala Asp Gln Glu Glu Glu Arg Lys
 100 105 110
 Ala Phe Met Glu Ala Gly Leu Asn His Cys Leu Glu Lys Pro Leu Thr
 115 120 125
 Lys Ala Lys Ile Phe Pro Leu Ile Ser His Leu Phe Asp Ala
 130 135 140

<210> 29
 <211> 1324
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1200)..(1322)

<220>
 <221> Unsure

<222> 1142

<223> n= any nucleotide

<400> 29

```

gtaatgcgac tcactatagg gcacgcgtgg tcgacggccc gggctgggtcc tcattcgtat 60
tgggccaat gggctactaa aacagtttca cgattgtttt tttttttttt tttttaattt 120
ttaacatgta tgtgggatat ttggctataa attatgtaaa aaatttcacg atagattgtt 180
gaatttttga atttcgagtt aaaatatctt caaattacct cacatttaca aaaaggtaga 240
actgttga aaactaatgct ctataaaaca ctagacaata aaaaaatacg taatgcgtaa 300
agaacctaaa ttatgatttt atttatcttt cttccttttt ccgtgagtat aagccatttt 360
tcatagtaaa gcattacgaa tacgacattg aacactactg acatataaag tagtagattt 420
tgatgggtta acttgatgct ttaatttgct taagcatgaa cttcaatgct tttataaaag 480
tacttcatga gaatattcct cgttctatac tagcagaagg gttcgatagt gattttacaa 540
ccgttcaaca aaacctttta acccaaaaaa ccaaagaatg aaagtatcta aacttgatta 600
tacatttctt gtctaaatta tcaaataaca tactctcttt tgtttactta taaacgatat 660
gaaagaaata aataaaaaaga acatagaatc ttattatgat ctagaagaat taattaaaga 720
aatatatata tattttttttt catttctact catgtttctt atacattctt taaatttggt 780
caccattttg atttacttgt tctcatatta gtttggtata caactcactt agaataatgt 840
agattacatt tcagccaaat tcatgtaaaa gatgcttttc tttgtgatgt ttttaaaatg 900
ctttcttttc actttttttc tttcttaact ataaatcttg atcgaatgcc taccttctta 960
gaacataaga tcttctttta aatccaaaat cgtaggccac tatttcatta tacttatgta 1020
atatatgtga tacagataca tntatatata aattaaacac gaaaccatac atgcacggtg 1080
tgatcacaca cgcacacaca tagaaacata aacacgcaat aatttctata cagtttaatt 1140
tcatttttaa cttacttctt tttttttggt gaagattctt gagagaaaag aaatcgaag 1199

atg gca aca aaa tcc acc gga ggt acc gag aaa acc aag tcg ata gaa 1247
Met Ala Thr Lys Ser Thr Gly Gly Thr Glu Lys Thr Lys Ser Ile Glu
  1             5             10             15

gtg aag aag aaa cta atc aac gtg ttg atc gtc gat gat gat cca tta 1295
Val Lys Lys Lys Leu Ile Asn Val Leu Ile Val Asp Asp Asp Pro Leu
          20             25             30

aac cgt aga ctc cac gag tgt cat caa aa 1324
Asn Arg Arg Leu His Glu Cys His Gln
      35             40

```

<210> 30
 <211> 41
 <212> PRT
 <213> Arabidopsis thaliana

<400> 30
 Met Ala Thr Lys Ser Thr Gly Gly Thr Glu Lys Thr Lys Ser Ile Glu
 1 5 10 15
 Val Lys Lys Lys Leu Ile Asn Val Leu Ile Val Asp Asp Asp Pro Leu
 20 25 30

Asn Arg Arg Leu His Glu Cys His Gln
 35 40

<210> 31
 <211> 1657
 <212> DNA
 <213> Brassica napus

<220>
 <221> CDS
 <222> (145) .. (1443)

<400> 31
 ggcatcacga gggtagccgt aaatcccacc atacaacaaa gttctgtgaa agtctcccaa 60
 aaactgcaaa gagtctcata ttagttctta ctctcagaaa taaaacacac tctttctgaa 120
 aagattagcg tttcaaaccg cgaa atg gcc cgt tgt cat gga agt ctt gct 171
 Met Ala Arg Cys His Gly Ser Leu Ala
 1 5
 att ttc tta tgc gtt ctt ttg atg ctc gct tgc tgc caa gct ttg agt 219
 Ile Phe Leu Cys Val Leu Leu Met Leu Ala Cys Cys Gln Ala Leu Ser
 10 15 20 25
 agc aac gta gat gat gga tat ggt cat gaa gat gga agc ttc gaa acc 267
 Ser Asn Val Asp Asp Gly Tyr Gly His Glu Asp Gly Ser Phe Glu Thr
 30 35 40
 gat agt tta atc aag ctc aac aac gac gac gac gtt ctt acc ttg aaa 315
 Asp Ser Leu Ile Lys Leu Asn Asn Asp Asp Asp Val Leu Thr Leu Lys
 45 50 55
 agc tcc gat aga ccc act acc gaa tca tca act gtt agt gtt tcg aac 363
 Ser Ser Asp Arg Pro Thr Thr Glu Ser Ser Thr Val Ser Val Ser Asn
 60 65 70
 ttc gga gca aaa ggt gat gga aaa acc gat gat act cag gct ttc aag 411
 Phe Gly Ala Lys Gly Asp Gly Lys Thr Asp Asp Thr Gln Ala Phe Lys
 75 80 85
 aaa gca tgg aag aag gca tgt tca aca aat gga gtg act act ttc ttg 459

Lys	Ala	Trp	Lys	Lys	Ala	Cys	Ser	Thr	Asn	Gly	Val	Thr	Thr	Phe	Leu	
90					95					100					105	
att	cct	aaa	ggg	aag	act	tat	ctc	ctt	aag	tct	att	aga	ttc	aga	ggc	507
Ile	Pro	Lys	Gly	Lys	Thr	Tyr	Leu	Leu	Lys	Ser	Ile	Arg	Phe	Arg	Gly	
				110					115					120		
cca	tgc	aaa	tca	tta	cgt	agc	ttc	cag	atc	cta	ggc	act	tta	tca	gct	555
Pro	Cys	Lys	Ser	Leu	Arg	Ser	Phe	Gln	Ile	Leu	Gly	Thr	Leu	Ser	Ala	
			125					130					135			
tct	aca	aaa	cga	tcg	gat	tac	agt	aat	gac	aag	aac	cac	tgg	ctt	att	603
Ser	Thr	Lys	Arg	Ser	Asp	Tyr	Ser	Asn	Asp	Lys	Asn	His	Trp	Leu	Ile	
		140					145					150				
ttg	gag	gac	gtt	aat	aat	cta	tca	atc	gat	ggc	ggc	tcg	gcg	ggg	att	651
Leu	Glu	Asp	Val	Asn	Asn	Leu	Ser	Ile	Asp	Gly	Gly	Ser	Ala	Gly	Ile	
	155					160					165					
gtt	gat	ggc	aac	gga	aaa	atc	tgg	tgg	caa	aac	tca	tgc	aaa	atc	gac	699
Val	Asp	Gly	Asn	Gly	Lys	Ile	Trp	Trp	Gln	Asn	Ser	Cys	Lys	Ile	Asp	
170				175						180					185	
aaa	tct	aag	cca	tgc	aca	aaa	gcg	cca	acg	gct	ctt	act	ctc	tac	aac	747
Lys	Ser	Lys	Pro	Cys	Thr	Lys	Ala	Pro	Thr	Ala	Leu	Thr	Leu	Tyr	Asn	
			190					195						200		
cta	aac	aat	ttg	aat	gtg	aag	aat	ctg	aga	gtg	aga	aat	gca	cag	cag	795
Leu	Asn	Asn	Leu	Asn	Val	Lys	Asn	Leu	Arg	Val	Arg	Asn	Ala	Gln	Gln	
			205					210					215			
att	cag	att	tcg	att	gag	aaa	tgc	aac	agt	gtt	gat	gtt	aag	aat	gtt	843
Ile	Gln	Ile	Ser	Ile	Glu	Lys	Cys	Asn	Ser	Val	Asp	Val	Lys	Asn	Val	
		220					225					230				
aag	atc	act	gct	cct	ggc	gat	agt	ccc	aac	acg	gat	ggt	att	cat	atc	891
Lys	Ile	Thr	Ala	Pro	Gly	Asp	Ser	Pro	Asn	Thr	Asp	Gly	Ile	His	Ile	
	235					240					245					
gtt	gct	act	aaa	aac	att	cga	atc	tcc	aat	tca	gac	att	ggg	aca	ggt	939
Val	Ala	Thr	Lys	Asn	Ile	Arg	Ile	Ser	Asn	Ser	Asp	Ile	Gly	Thr	Gly	
	250				255				260						265	
gat	gat	tgc	ata	tcc	att	gag	gat	gga	tcg	caa	aat	gtt	caa	atc	aat	987
Asp	Asp	Cys	Ile	Ser	Ile	Glu	Asp	Gly	Ser	Gln	Asn	Val	Gln	Ile	Asn	
			270					275						280		
gat	tta	act	tgc	ggc	ccc	ggt	cat	ggc	atc	agc	att	gga	agc	ttg	ggg	1035
Asp	Leu	Thr	Cys	Gly	Pro	Gly	His	Gly	Ile	Ser	Ile	Gly	Ser	Leu	Gly	
			285					290					295			
gat	gac	aat	tcc	aaa	gct	tat	gta	tcg	gga	att	aat	gtg	gat	ggt	gct	1083
Asp	Asp	Asn	Ser	Lys	Ala	Tyr	Val	Ser	Gly	Ile	Asn	Val	Asp	Gly	Ala	
		300					305					310				
acg	ctc	tct	gag	act	gac	aat	gga	gta	aga	atc	aag	act	tac	cag	gga	1131

Thr	Leu	Ser	Glu	Thr	Asp	Asn	Gly	Val	Arg	Ile	Lys	Thr	Tyr	Gln	Gly		
315						320					325						
ggg	tca	gga	act	gct	aag	aac	att	aaa	ttc	caa	aac	att	cgt	atg	gat	1179	
Gly	Ser	Gly	Thr	Ala	Lys	Asn	Ile	Lys	Phe	Gln	Asn	Ile	Arg	Met	Asp		
330					335					340					345		
aat	gtc	aag	aat	ccg	atc	ata	atc	gac	cag	aac	tac	tgc	gac	aag	gac	1227	
Asn	Val	Lys	Asn	Pro	Ile	Ile	Ile	Asp	Gln	Asn	Tyr	Cys	Asp	Lys	Asp		
				350					355					360			
aaa	tgc	gaa	caa	caa	gaa	tct	gcg	gtt	caa	gtg	aac	aat	gtc	gtg	tat	1275	
Lys	Cys	Glu	Gln	Gln	Glu	Ser	Ala	Val	Gln	Val	Asn	Asn	Val	Val	Tyr		
			365					370					375				
cgg	aac	ata	caa	ggg	acg	agc	gca	acg	gat	gtg	gcg	ata	atg	ttt	aat	1323	
Arg	Asn	Ile	Gln	Gly	Thr	Ser	Ala	Thr	Asp	Val	Ala	Ile	Met	Phe	Asn		
		380					385					390					
tgc	agt	gtg	aaa	tat	cca	tgc	caa	ggg	att	gtg	ctt	gag	aat	gtg	aac	1371	
Cys	Ser	Val	Lys	Tyr	Pro	Cys	Gln	Gly	Ile	Val	Leu	Glu	Asn	Val	Asn		
	395					400					405						
atc	aaa	gga	gga	aaa	gct	tct	tgc	aaa	aat	gtc	aat	gtt	aag	gat	aaa	1419	
Ile	Lys	Gly	Gly	Lys	Ala	Ser	Cys	Lys	Asn	Val	Asn	Val	Lys	Asp	Lys		
410					415					420					425		
ggc	acc	gtt	tct	cct	aaa	tgc	cct	taattactaa	ggtgattatg	taatatacat						1473	
Gly	Thr	Val	Ser	Pro	Lys	Cys	Pro										
				430													
aaatacgtat	tatatgtggt	tatagatgcc	atctatatcc	ttatctacgt	attgattctc											1533	
gatatatata	gaaaactaag	gatttatggg	aatatacata	caatagttga	gataattggt											1593	
gtcttgtata	tggttcactg	aagttgattg	cttgtccaacg	aataaatgaa	taatgtcatt											1653	
tgtc																	1657
<210> 32																	
<211> 433																	
<212> PRT																	
<213> Brassica napus																	
<400> 32																	
Met	Ala	Arg	Cys	His	Gly	Ser	Leu	Ala	Ile	Phe	Leu	Cys	Val	Leu	Leu		
1				5					10					15			
Met	Leu	Ala	Cys	Cys	Gln	Ala	Leu	Ser	Ser	Asn	Val	Asp	Asp	Gly	Tyr		
			20					25					30				
Gly	His	Glu	Asp	Gly	Ser	Phe	Glu	Thr	Asp	Ser	Leu	Ile	Lys	Leu	Asn		
		35					40					45					
Asn	Asp	Asp	Asp	Val	Leu	Thr	Leu	Lys	Ser	Ser	Asp	Arg	Pro	Thr	Thr		

50					55					60					
Glu 65	Ser	Ser	Thr	Val	Ser 70	Val	Ser	Asn	Phe	Gly 75	Ala	Lys	Gly	Asp	Gly 80
Lys	Thr	Asp	Asp	Thr 85	Gln	Ala	Phe	Lys	Lys 90	Ala	Trp	Lys	Lys	Ala	Cys 95
Ser	Thr	Asn	Gly 100	Val	Thr	Thr	Phe	Leu 105	Ile	Pro	Lys	Gly	Lys	Thr	Tyr
Leu	Leu	Lys 115	Ser	Ile	Arg	Phe	Arg 120	Gly	Pro	Cys	Lys	Ser 125	Leu	Arg	Ser
Phe 130	Gln	Ile	Leu	Gly	Thr	Leu 135	Ser	Ala	Ser	Thr	Lys 140	Arg	Ser	Asp	Tyr
Ser 145	Asn	Asp	Lys	Asn	His 150	Trp	Leu	Ile	Leu	Glu 155	Asp	Val	Asn	Asn	Leu 160
Ser	Ile	Asp	Gly 165	Gly	Ser	Ala	Gly	Ile	Val 170	Asp	Gly	Asn	Gly	Lys	Ile 175
Trp	Trp	Gln 180	Asn	Ser	Cys	Lys	Ile	Asp 185	Lys	Ser	Lys	Pro	Cys	Thr	Lys
Ala	Pro	Thr 195	Ala	Leu	Thr	Leu	Tyr 200	Asn	Leu	Asn	Asn	Leu 205	Asn	Val	Lys
Asn 210	Leu	Arg	Val	Arg	Asn	Ala 215	Gln	Gln	Ile	Gln	Ile	Ser	Ile	Glu	Lys
Cys 225	Asn	Ser	Val	Asp	Val 230	Lys	Asn	Val	Lys	Ile 235	Thr	Ala	Pro	Gly	Asp 240
Ser	Pro	Asn	Thr 245	Asp	Gly	Ile	His	Ile	Val 250	Ala	Thr	Lys	Asn	Ile	Arg 255
Ile	Ser	Asn 260	Ser	Asp	Ile	Gly	Thr	Gly 265	Asp	Asp	Cys	Ile	Ser	Ile	Glu
Asp	Gly 275	Ser	Gln	Asn	Val	Gln	Ile 280	Asn	Asp	Leu	Thr	Cys 285	Gly	Pro	Gly
His 290	Gly	Ile	Ser	Ile	Gly	Ser 295	Leu	Gly	Asp	Asp	Asn 300	Ser	Lys	Ala	Tyr
Val 305	Ser	Gly	Ile	Asn	Val 310	Asp	Gly	Ala	Thr	Leu 315	Ser	Glu	Thr	Asp	Asn 320
Gly	Val	Arg	Ile 325	Lys	Thr	Tyr	Gln	Gly	Gly 330	Ser	Gly	Thr	Ala	Lys	Asn 335
Ile	Lys	Phe 340	Gln	Asn	Ile	Arg	Met 345	Asp	Asn	Val	Lys	Asn	Pro	Ile	Ile 350

[illegible]

gttcttaciaa attcttcgtg aggttttcag ctgttaccac taatattttt tcaaaatcga 401
 ttttatttta cttgtaattt aaaagatcaa atattaatac aatgaacatt tttgtaacag 461
 caatctttttt tttatatttt ggagatttca tcgacttatg tcataattat ttttatcaat 521
 ttattgttgt ttgttagtga tataataaag tatattttct ggtcaaaa 569

<210> 34
 <211> 103
 <212> PRT
 <213> Brassica napus

<400> 34
 Val Thr Val Ala Asp Gly Asn Val Leu Val Lys Arg Glu Val Asp Gly
 1 5 10 15
 Gly Leu Glu Thr Val Lys Val Lys Leu Pro Ala Val Ile Ser Ala Asp
 20 25 30
 Leu Arg Leu Asn Glu Pro Arg Tyr Ala Thr Leu Pro Asn Ile Met Lys
 35 40 45
 Ala Lys Lys Lys Pro Ile Lys Lys Leu Thr Ala Thr Asp Val Gly Val
 50 55 60
 Asp Leu Ala Pro Arg Gln Gln Val Leu Ser Val Glu Asp Pro Pro Thr
 65 70 75 80
 Arg Gln Ala Gly Ser Ile Val Pro Asp Val Asp Thr Leu Ile Thr Lys
 85 90 95
 Leu Lys Glu Lys Gly His Leu
 100

<210> 35
 <211> 306
 <212> DNA
 <213> Brassica napus

<220>
 <221> CDS
 <222> (3) .. (305)

<400> 35
 gg ttg ggt cga acc ata ggt gga aag ctt ctt tct ctc tcg ctt gac 47
 Leu Gly Arg Thr Ile Gly Gly Lys Leu Ser Leu Ser Leu Asp
 1 5 10 15
 aaa tcc tct ggt tcg ggt ttt cag tcc cat cag gag ttt ctc tat ggt 95
 Lys Ser Ser Gly Ser Gly Phe Gln Ser His Gln Glu Phe Leu Tyr Gly
 20 25 30
 aaa gct gag gtt caa atg aaa ctt gtc cct ggt aac tct gct gga aca 143

Lys	Ala	Glu	Val	Gln	Met	Lys	Leu	Val	Pro	Gly	Asn	Ser	Ala	Gly	Thr		
			35					40					45				
gtc	aca	aca	ttc	tat	ctt	aaa	tca	ccg	gga	act	aca	tgg	gat	gag	atc	191	
Val	Thr	Thr	Phe	Tyr	Leu	Lys	Ser	Pro	Gly	Thr	Thr	Trp	Asp	Glu	Ile		
		50					55					60					
gat	ttc	gag	ttc	ttg	gga	aac	ata	agt	ggc	cat	ccc	tat	act	ctc	cat	239	
Asp	Phe	Glu	Phe	Leu	Gly	Asn	Ile	Ser	Gly	His	Pro	Tyr	Thr	Leu	His		
	65					70				75							
act	aat	gtt	tac	aca	cga	agg	ctc	tgg	aga	caa	aga	aca	gca	gtt	tca	287	
Thr	Asn	Val	Tyr	Thr	Arg	Arg	Leu	Trp	Arg	Gln	Arg	Thr	Ala	Val	Ser		
	80				85				90						95		
tct	atg	gtt	cga	ccc	gac	c										306	
Ser	Met	Val	Arg	Pro	Asp												
			100														

<210> 36
 <211> 101
 <212> PRT
 <213> Brassica napus

<400> 36																	
Leu	Gly	Arg	Thr	Ile	Gly	Gly	Lys	Leu	Leu	Ser	Leu	Ser	Leu	Asp	Lys		
1				5				10						15			
Ser	Ser	Gly	Ser	Gly	Phe	Gln	Ser	His	Gln	Glu	Phe	Leu	Tyr	Gly	Lys		
		20					25						30				
Ala	Glu	Val	Gln	Met	Lys	Leu	Val	Pro	Gly	Asn	Ser	Ala	Gly	Thr	Val		
		35					40					45					
Thr	Thr	Phe	Tyr	Leu	Lys	Ser	Pro	Gly	Thr	Thr	Trp	Asp	Glu	Ile	Asp		
		50				55					60						
Phe	Glu	Phe	Leu	Gly	Asn	Ile	Ser	Gly	His	Pro	Tyr	Thr	Leu	His	Thr		
	65				70				75					80			
Asn	Val	Tyr	Thr	Arg	Arg	Leu	Trp	Arg	Gln	Arg	Thr	Ala	Val	Ser	Ser		
				85					90					95			
Met	Val	Arg	Pro	Asp													
			100														

<210> 37
 <211> 27
 <212> DNA
 <213> Artifical Sequence

<220>
 <223> GW1

27

<213> Artificial Sequence

<223> AT3GW2

27

534 Rec'd PCT/PTO 20 SEP 2000
SIGNAL TRANSDUCTION PROTEIN INVOLVED
IN PLANT DEHISCENCE

5 This invention relates to novel plant nucleic acid sequences and proteins. The sequences and proteins are useful in the control of plant dehiscence and in the production of male sterile plants.

10 The production of seed is an important developmental process in all higher plants. In oilseed rape (*Brassica napus*), following abscission of floral parts, pods or siliques are formed which contain 15-30 seeds. Around 50-70 days after anthesis (DAA) the pods become susceptible to shatter, a process that serves to expel the mature seeds into the surrounding environment. In the days leading to dehiscence, an array of anatomical, molecular and biochemical changes take place, thus
15 preparing both seed and pod for the event. Shatter eventually occurs as a result of a combination of factors including: the creation of tensions within the pod between the lignified valve edge cells of the endocarp and the unlignified dehiscence zone (DZ) cells, weakening of the DZ cell walls by hydrolytic enzyme activity and ultimately due to physical forces such as strong winds or harvesting machinery.

20 Pod development in *B. napus* can be segmented into three stages. In the first stage, which occurs 0-20 DAA, the newly formed siliques, consisting of two seed-containing carpels separated by a false septum and a replar region, grow to their full length of around 10cm. The seeds begin to grow when the pods are virtually full size [Hocking and Mason, 1993]. Between 10 and 20 DAA the cells in the replar
25 region begin to differentiate into replar cells, large valve edge cells and form a distinct region, 1-3 cells wide, comprising the DZ [Meakin and Roberts, 1990a].

The second stage occurs between 20 and 50 DAA. From 20 DAA, in conjunction

- with termination of pod elongation, secondary cell wall material is deposited in the valve edge cells, and the replar cells become increasingly lignified. The DZ cells do not exhibit thickening of the cell wall. A progressive shrinkage and loss of organelles is apparent in the DZ cells from 40 DAA onwards and eventually these cells separate completely due to hydrolysis of the middle lamella [Meakin and Roberts, 1990a]. In the final stage of pod development, which occurs 50-70 DAA, the lignified cells undergo senescence and the necessary tensions are created so that the desiccated pod, containing mature seed, eventually shatters.
- 10 Molecular studies of the penultimate stage of pod development have revealed a spatial and temporal correlation between the up-regulation of a number of mRNAs and pod dehiscence in *B. napus*. These mRNAs encode a polygalacturonase (PG) and a proline-rich protein (SAC51). Further analysis of the expression of the PG following fusion of a pod-specific *Arabidopsis thaliana* PG promoter to GUS [Jenkins et al., (1997)], has revealed that reporter gene expression is restricted precisely to the layer of cells comprising the pod DZ in transgenic *B. napus*. From 40 DAA, Meakin and Roberts (1990b) reported a progressive increase in β -1,4-glucanase (cellulase) activity in the DZ.
- 20 It is understood that the processes of dehiscence and abscission are not regulated by the same environmental or chemical signals, but that they involve controlled degradation of cell wall material and cell separation in a distinct group of cells. Both ethylene and indole-3-acetic acid (IAA) appear to be important regulators of the timing of the abscission process but the role of these plant hormones in dehiscence is less clearly defined. The increase in cellulase activity has been shown to correlate with a rise in the production of ethylene, mainly from the seed, which peaks at around 40 DAA [Meakin and Roberts, 1990b; Johnson-Flanagan and Spencer, 1994].

Developmental processes, such as pod dehiscence, which involve highly regulated and controlled expression of an array of different genes at a precise time and cellular location, clearly require an intricate signal transduction network.

5 Further and improved genetic elements to control plant processes in this area are constantly desired. We describe the isolation, for the first time, of a plant cDNA (DZ2) encoding an individual response regulator protein, the expression of which is closely correlated with dehiscence of fruit in *B. napus*. DZ2 has a role in the ability to control molecule signaling during the events leading to shatter and thus to control pod shatter in plants. In addition to the identification of the nucleic acid termed "DZ2" a homologous, but not identical sequence and protein were also identified from *B. napus*. This sequence was designated "DZ2B". Sequence analysis of DZ2 and DZ2B shows that there are two DZ2 genes in *B. napus*, each represented by a slightly different cDNA (here termed DZ2 and DZ2B). This is consistent with one gene being encoded by the *B. campestris* derived genome and the other from the genome derived from *B. oleracea*. In this text, the designation "DZ2" is equivalent to the CW1 designation in UK 9806113.8 (as seen from Figure 1).

20 According to a first aspect of the invention there is provided nucleic acid optionally encoding a signal transduction protein involved in the process of dehiscence. Such a sequence or signal transduction protein has never previously been described in plant dehiscence.

25 In this text, the term "involved in the process of dehiscence" means any nucleic acid (preferably) encoding any protein which has an effect in the dehiscence process, in particular a protein or nucleic acid sequence involved in an MAP Kinase cascade or any other protein or nucleic acid sequence which results in changes in the expression of genes involved in dehiscence, such as upregulation of genes encoding

polygalacturonase, cellulase, senescence-related proteins and/or downregulation of genes encoding for proteins involved in cell wall biosynthesis. The nucleic acid sequences/proteins of the present invention which are "involved in the process of plant dehiscence" are not the individual structural genes or proteins which cause
5 dehiscence (polygalacturonases etc.). Rather, the nucleic acid sequences/proteins of the present invention are sequences/proteins which have an effect on the expression of such structural genes or proteins. One advantage of the present invention is that the use of such nucleic acid sequences/proteins enables the possibility to influence the whole process of dehiscence rather than just one element of it. Preferably the
10 protein or nucleic acid sequence of the present invention which is involved in the process of dehiscence effects a structural protein which is a hydrolytic enzyme such as polygalacturonase or cellulase.

The nucleic acid of the first aspect of the invention may be a nucleic acid which is
15 naturally expressed in a dehiscence zone. Such a nucleic acid will most accurately reflect nucleic acid naturally expressed in a plant. Preferably the dehiscence zone is a pod (also termed "siliques"), anther and/or funiculus dehiscence zone. Preferably the plant is a member of the Brassica family, maize, wheat, soyabean, *Cuphea* or sesame.

20 A second aspect of the invention provides nucleic acid encoding a protein wherein the protein:

- 25
- a) comprises the amino acid sequence shown in figure 1 or;
 - b) has one or more amino acid deletions, insertions or substitutions relative to a protein as defined in a) above, but has at least 40% amino acid sequence identical therewith; or

- c) is a fragment of a protein as defined in a) or b) above, which is at least 10 (preferably 20 or 30) amino acids long.

- 5 The percentage amino acid identity can be determined using the default parameters of the GAP computer program, version 6.0 described by Deveraux *et al.*, 1984 and available from the University of Wisconsin Genetics Computer Group (UWGCG). The GAP program utilises the alignment method of Needleman and Wunsch 1970 as revised by Smith and Waterman 1981. More preferably the protein has at least 45%
10 identity to the amino acid sequence of Figure 1, through 50%, 55% 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% identity using the default parameters.

- The skilled person will appreciate that various changes can sometimes be made to the amino acid sequence of a protein (which has a desired property) to produce
15 variants (often known as "muteins") which still have said property. Such variants of the protein describe in a, b and c above are within the scope of the present invention and are discussed in greater detail below in sections (i) to (iii). They include allelic and non-allelic variants.

20 (i) *Substitutions*

An example of a variant of the present invention is a polypeptide as defined in a, b or c above, apart from the substitution of one or more amino acids with one or more other amino acids.

- 25 The skilled person is aware that various amino acids have similar characteristics. One or more such amino acids of a protein can often be substituted by one or more other such amino acids without eliminating a desired property of that protein.

For example, the amino acids glycine, alanine, valine, leucine and isoleucine can often be substituted for one another (amino acids having aliphatic side chains). Of these possible substitutions it is preferred that glycine and alanine are used to substitute for one another (since they have relatively short side chains) and that
5 valine, leucine and isoleucine are used to substitute for one another (since they have larger aliphatic side chains which are hydrophobic). Other amino acids that can often be substituted for one another include phenylalanine, tyrosine and tryptophan (amino acids having aromatic side chains); lysine, arginine and histidine (amino acids having basic side chains); aspartate and glutamate (amino acids having acidic
10 side chains); asparagine and glutamine (amino acids having amide side chains); and cysteine and methionine (amino acids having sulphur containing side chains).

Substitutions of this nature are often referred to as "conservative" or "semi-conservative" amino acid substitutions.

15

(ii) *Deletions*

Amino acid deletions can be advantageous since the overall length and the molecular weight of a polypeptide can be reduced whilst still retaining a desired property. This can enable the amount of protein required for a particular purpose to be reduced.
20 Proteins according to the present invention, which have such deletion(s) are useful. They may interfere with the normal functioning of DZ2; that is, they may act as dominant negative mutations preventing normal DZ2 functioning and thus be of particular value, for example, in reducing pod shatter.

25 The amino acid sequence shown in figure 1 has various functional regions. For particular applications of the present invention, one or more of these regions may not be needed and may therefore be deleted.

(iii) *Insertions*

Amino acid insertions relative to a polypeptide as defined in a, b or c above can also be made. This may be done to alter the nature of the protein (e.g. to assist in identification, purification, or expression, as explained below in relation to fusion proteins).

Changes in the protein according to the present invention can produce versions of the protein that are constitutively active. If a protein of the present invention acts on an inhibitor of the release of hydrolytic enzymes, then a constitutively active version would prevent or reduce pod shatter

A protein according to any aspect of the invention may have additional N-terminal and/or C-terminal amino acid sequences. Such sequences can be provided for various reasons. Techniques for providing such sequences are well known in the art. They include using gene-cloning techniques to ligate together nucleic acid molecules encoding polypeptides or parts thereof, followed by expressing a polypeptide encoded by the nucleic acid molecule produced by ligation.

Additional sequences may be provided in order to alter the characteristics of a particular polypeptide. This can be useful in improving expression or regulation of expression in particular expression systems. For example, an additional sequence may provide some protection against proteolytic cleavage. This has been done for the hormone somatostatin by fusing it at its N-terminus to part of the β galactosidase enzyme [Itakwa *et al.*, 105-63 (1977)].

Additional sequences can also be useful in altering the properties of a polypeptide to aid in identification or purification.

For example, a signal sequence may be present to direct the transport of the polypeptide to a particular location within a cell or to export the polypeptide from the cell. Hydrophobic sequences may be provided to anchor a polypeptide in a membrane. Thus the present invention includes within its scope both soluble and
5 membrane-bound polypeptides.

Preferably, the nucleic acid according to the second aspect of the invention encodes a signal transduction protein or a functional portion thereof involved in the process of dehiscence. All preferred features of the first aspect of the invention as described
10 above also apply to the second.

The term protein used in this text means, in general terms, a plurality of amino acid residues joined together by peptide bonds. It is used interchangeably and means the same as polypeptide or peptide.
15

The nucleic acid according to the first or second aspect of the invention preferably comprises the sequence set out in figure 1 or a sequence which is 40% or more identical, preferably through 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% to the sequence in Figure 1 at the nucleic acid residue level, using the
20 default parameters of the GAP computer program, version 6.0 described by Deveraux *et al.*, 1984 and available from the University of Wisconsin Genetics Computer Group (UWGCG). The GAP program utilises the alignment method of Needleman and Wunsch 1970 as revised by Smith and Waterman 1981. Further, the nucleic acid may comprise a fragment of a sequence according to the first or second
25 aspect which is at least 30 bases long also 40, 50, 60, 70, 80, or 90 bases in length. While this nucleic acid is the preferred nucleic acid of the invention, it is well known to those persons skilled in the art that because of the nucleic acid "degenerate code" which encodes nucleic acids, a considerable number of variations in nucleic acid

sequence can be used to encode for proteins according to the first or second aspects of the invention.

5 The nucleic acid of the first or second aspects of the invention may be isolated or recombinant and may be in substantially pure form. The nucleic acid may be antisense to nucleic acid according to the first or second aspects of the invention. As understood by the person skilled in the art introducing the coding region of a gene in the reverse orientation to that found in nature (antisense) can result in the downregulation of the gene and hence the production of less or none of the gene product. The transcribed antisense DNA is capable of binding to and destroying the function of the sense RNA of the sequence normally found in the cell, thereby disrupting function. Antisense nucleic acid may be constitutively expressed, but is preferably limited to expression in those zones (dehiscence) in which the naturally occurring nucleic acid is expressed.

15 The nucleic acid according to the first or second aspects of the invention preferably include a promoter or other regulatory sequence which controls expression of the nucleic acid. Promoters and other regulatory sequences which control expression of a nucleic acid in dehiscence zones are known in the art, for example described in WO96/30529 and WO94/23043. Further promoters or other regulatory sequences can be identified and can also include the promoter or other regulatory sequence which controls expression of a nucleic acid as set out in figure 1. The person skilled in the art will know that it may not be necessary to utilize the whole promoter or other regulatory sequence. Only the minimum essential regulatory elements may be required and in fact such elements can be used to construct chimeric sequences or promoters. The essential requirement is, of course, to retain the tissue and/or temporal specificity.

The nucleic acid according to the first or second aspects of the invention may be in the form of a vector. The vector may be a plasmid, cosmid or phage. Vectors frequently include one or more expressed markers which enable selection of cells transfected (or transformed: the terms are used interchangeably in this text) with them and preferably, to enable a selection of cells containing vectors incorporating heterologous DNA. A suitable start and stop signal will generally be present and if the vector is intended for expression, sufficient regulatory sequences to drive expression will be present. Nucleic acid according to the first and second aspects of the invention is preferably for expression in plant cells and thus microbial host expression is perhaps less important although not ruled out. Microbial host expression and vectors not including regulatory sequences are useful as cloning vectors.

A third aspect of the invention relates to a cell comprising nucleic acid according to the first or second aspects of the invention. The cell may be termed as "a host" which is useful for manipulation of the nucleic acid, including cloning. Alternatively, the cell may be a cell in which to obtain expression of the nucleic acid, most preferably a plant cell. The nucleic acid can be incorporated by standard techniques known in the art in to cells. Preferably nucleic acid is transformed in to plant cells using a disarmed Ti plasmid vector and carried by an Agrobacterium by procedures known in the art, for example as described in EP-A-0116718 and EP-A-0270822. Foreign nucleic acid can alternatively be introduced directly into plant cells using an electrical discharged apparatus or by any other method that provides for the stable incorporation of the nucleic acid into the cell. Preferably the stable incorporation of the nucleic acid is within the nucleic DNA of any cell preferably a plant cell. Nucleic acid according to the first and second aspects of the invention preferably contains a second "marker" gene that enables identification of the nucleic acid. This is most commonly used to distinguish the transformed plant cell

- containing the foreign nucleic acid from other plants cells that do not contain the foreign nucleic acid. Examples of such marker genes include antibiotic resistance, herbicide resistance and Glucuronidase (GUS) expression. Expression of the marker gene is preferably controlled by a second promoter which allows expression of the marker gene in cells other than those than dehiscence zones (if this is the tissue specific expression of the nucleic acid according to the first or second aspects of the invention). Preferably the cell is from any of the Brassica family (most preferably *B. napus*), maize, wheat, soyabean, *Cuphea* and sesame.
- 10 A third aspect of the invention includes a process for obtaining a cell comprising nucleic acid according to the first or second aspects of the invention. The process involves introducing said nucleic acid into a suitable cell and optionally growing on or culturing said cell.
- 15 A fourth aspect of the invention provides a plant or a part thereof comprising a cell according to the third aspect of the invention. A whole plant can be regenerated from the single transformed plant cell by procedures well known in the art. The invention also provides for propagating material or a seed comprising a cell according to the third aspect of the invention. The invention also relates to any plant or part thereof including propagating material or a seed derived from any aspect of the invention. The fourth aspect of the invention also includes a process for obtaining a plant or plant part (including propagating material or seed, the process comprising obtaining a cell according to the third aspect of the invention or, indeed, plant material according to the fourth aspect of the invention and growth (to the required plant, plant part, propagating material etc). Techniques for such a process are commonplace in the art.
- 25

A fifth aspect of the invention provides a signal transduction protein involved in the

process of the plant dehiscence. The signal transduction protein according to the fifth aspect may have one or more of the preferred features according to the first or second aspects of the invention. Preferably it may be isolated, recombinant or in substantially pure form. It may comprise the various changes according to the first or second aspects. Preferably the protein is expressed from nucleic acid according to the first or second aspects. Alternatively, the protein can be provided using suitable techniques known in the art.

A sixth aspect of the invention provides a protein which;

- a) comprises the amino acid sequence shown in figure 1 or;
- b) has one or more amino acid deletions, insertions, or substitutions relative to a protein as defined in a) above and has at least 40% amino acid sequence identity therewith;

or a fragment of a protein as defined in a) or b) above which is at least 10 amino acids long. The percentage amino acid identity can be determined using the default parameters of the GAP computer program, version 6.0 described by Deveraux *et al.*, 1984 and available from the University of Wisconsin Genetics Computer Group (UWGCG). The GAP program utilises the alignment method of Needleman and Wunsch 1970 as revised by Smith and Waterman 1981. More preferably the protein has at least 45% identity to the amino acid sequence of Figure 1, through 50%, 55% 60%, 65%, 70%, 75% 80%, 85%, 90%, 95% identity using the default parameters.

The protein is preferably a signal transduction protein involved in the process of plant dehiscence and again, the preferred features of aspects one, two and five also applied to the sixth aspect.

The seventh aspect of the invention provides a process for regulating/controlling dehiscence in plant or in a part thereof, the process comprising obtaining a plant or a part thereof according to the fourth aspect of the invention. The process of dehiscence can be regulated and/or controlled by increasing or decreasing the
5 expression of nucleic acid sequences according to the first or second aspect of the invention. Increased or decreased expression can easily be influenced by the person skilled in the art using technology well known. This includes increasing the numbers of copies of nucleic acid according to the invention in a plant or a plant thereof or increasing expression levels of copies of the nucleic acid present in
10 particular parts or zones of the plant. Preferably the zones are dehiscence zones.

The process according to the seventh aspect of the invention includes obtaining a plant cell according to the third aspect of the invention or part of a plant according to the fourth aspect in the invention and deriving a plant therefrom. Alternatively, the
15 process may comprise obtaining propagating material or a seed according to the fourth aspect of the invention and deriving a plant therefrom.

Preferably, the process of the seventh aspect of the invention is in the pod or the anther of a plant. All preferred features of aspects one to six also apply to the
20 seventh.

An eighth aspect of the invention provides for the use of nucleic acid according to the first to seventh aspects of the invention in the regulation/control of plant dehiscence. All preferred features of aspects one to seven also applies to the eighth.
25

The ninth aspect of the invention provides for the use of nucleic acid according to the first or second aspect of the invention as a probe. Such a probe can be used in techniques well known in the art to identify the presence of identical or homologous

nucleic acid sequences from any source, preferably a plant source. The ninth aspect of the invention also provides nucleic acid identified by use of the nucleic acid from aspects one or two as a probe.

5 A tenth aspect of the invention provides for the use of nucleic acid according to aspects one or two of the invention in the production of a cell, tissue, plant or part thereof, or propagating material. Again, all preferred features of aspects one and two also apply to the tenth.

10 An eleventh aspect of the invention provides for nucleic acid comprising one or more of the underlined sequences as set out in figure 1 or the primer sequences in Fig 5, Fig 9 or Fig 11. Such nucleic acid sequences are preferably used as primers in an PCR (Polymerase Chain Reaction) process in order to amplify nucleic acid sequences.

15 A twelfth aspect of the invention provides the use of nucleic acid according to the first or second aspects of the invention to identify another other protein or proteins which interact with its expression product. Such use can be carried out by the yeast two hybrid screening method (or others known in the art). The yeast two hybrid
20 screening method is described for this aspect of the invention, in general, with reference to the sequence described as DZ2. A potential way to implement the yeast 2-hybrid screen is outlined, as follows:

25 DZ2 is linked to the Gal4 DNA binding domain and expressed in yeast which contains a pGAL4-lacZ gene. For activity of lacZ a second protein is required that contains the DNA transcriptional activation domain of GAL4 and that interacts with the DZ2 protein. This is provided by making a cDNA expression library from plant DZ zones which results in fusions of plant

proteins to the GAL4 activation domain. This library is transformed into the yeast strain that contains pGAL4-LacZ and expresses the DZ2-Gal4 DNA binding domain protein fusion. Colonies that have lacZ activity are transformed with a gene for a protein that interacts with DZ2.

5

Using such a system, upstream and downstream components of any signal transduction pathway can be identified, thus resulting in further ability to control/regulate dehiscence and/or male sterility.

10 A thirteenth aspect of the invention provides for a protein, as defined according to the limitations of the second aspect of the invention (without reference to figure 1) and nucleic acid encoding the protein, wherein the protein is capable of being identified according to the use (or method) according to the twelfth aspect of the invention.

15

A fourteenth aspect of the invention provides for the use of a protein according to the fifth or sixth aspect of the invention as a probe. In this context the probe is a means to identifying interacting entities (such as other proteins), including upstream and downstream interacting signal components. A protein according to the fifth or
20 sixth aspect of the invention can be used as a probe to directly look for interactions with other proteins, i.e. purified protein can be used to look for complex formation with other plant protein, particularly isolated from the DZ zone. For example, a modified recombinant DZ2 protein can be made with a sequence tag, such as a His-tag, that enables the DZ2 + interacting protein to be directly purified on a His
25 affinity column. Alternatively, an antibody can be raised to DZ2 protein. This antibody is then used to identify DZ2 protein complexes and to purify the complexes. The DZ2 interacting proteins can be purified and microsequenced to enable cloning of the genes for these interacting proteins.

The present invention provides a particularly useful method by which plant dehiscence can be regulated/controlled.

- 5 In addition to the use of the present invention in the production of shatter resistance or shatter-delayed plants such as oil seed rape, the invention may be used to control/regulate pollen release (by the control/regulation of anther dehiscence) which can produce male sterile plants. The temporal and spatial expression of nucleic acid encoding a protein according to the first and second aspects of the invention may
- 10 require adjustment in obtaining the correct levels of dehiscence delay or prevention in different zones. For example, if pod dehiscence is required but anther dehiscence is not, it is necessary to ensure that expression of nucleic acid according to a first or second aspect of the invention has the correct temporal and spatial expression in order to obtain pod dehiscence or delay but not, to any substantial extent, anther
- 15 dehiscence. This can be obtained by processes known in the art and may require use of particular promoter sequences to obtain the desired result. Usually in plant transformation, some difference in the level of expression of nucleic acid is observed in different plants. In some cases, the ratio of expression levels in different tissues can vary between different plant transformants thus providing essentially tissue-
- 20 specific expression in one or other of the target tissues in some of the plant transformants. In the present invention, the natural expression of nucleic acid according to the first or second aspects may be predominantly higher in pod dehiscence zones and lower in the anther and funiculus dehiscence zones. However, as described above, it is possible to obtain plants in which the protein expression is
- 25 regulated in a particular dehiscence zone. Accordingly, a particularly useful aspect of the invention is the provision of plants which have one or both of the following features; are male sterile, are shatter resistant.

As described earlier, the process of dehiscence at the dehiscence zone involves the secretion of a number of enzymes, including hydrolytic enzymes. While previous attempts have been made to down or up regulate specific genes encoding particular proteins involved in the process of dehiscence, regulation by means of a signal transduction protein which effects expression of a number of genes is likely to be more effective than regulation of a single gene. In addition to this, the nucleic acid of the present invention has been identified as being expressed earlier than several other known genes involved in the process of plant dehiscence. This suggests that it is important earlier on in the process of plant dehiscence and can be used to control/regulate plant dehiscence at an earlier stage.

The nucleic acid encoding a signal transduction protein involved in the process of dehiscence or the signal transduction protein itself may be a component of a signal pathway that may either positively or negatively regulate pod shatter.

A more detailed explanation of such regulations/control, described with reference to a pod shatter (dehiscence) model is described below. As a skilled person will acknowledge, the model described below also relates to other general processes of dehiscence such as in the anther.

In the process of dehiscence, a particular signal transduction protein may be required to transmit a signal from the almost mature seed which initiates the expression or release of enzymes required for pod shatter. In this model, developmental signals switch on expression and/or activation of a particular signal transduction protein in the pod dehiscence zone. This leads to expression of genes required for the release of pod dehiscence zone enzymes (such as hydrolytic enzymes). In this case, prevention of activity of the signal transduction protein, for example by downregulation of expression of this protein, would result in reduced dehiscence.

Alternatively, the developing seed may transmit a signal which represses the expression and/or activity of a particular signal transduction protein until late in cell development. In this model, developmental signals switch on a particular signal
5 transduction protein which, in due course, represses the expression of genes required for release of dehiscence zone specific enzymes (such as hydrolytic enzymes). In this case, expression of a modified signal transduction protein that is constitutively active would result in reduced dehiscence.

10 A signal transduction protein which is either positively or negatively involved in the process of dehiscence can be used according to the present invention.

In addition to DZ2 several other DZ-expressed genes have been previously isolated and individually downregulated to result in *B. napus* plants that have increased
15 resistance to pod shatter; namely Sac66 (WO 96/30529 - Figure 15), DZ15 (Figure 16) and OSR 7(9) (Figure 17). It is anticipated that downregulation of more than one gene involved in pod shatter will further increase resistance to pod shatter. This could be achieved by combining different transgenes by transformation with several transgenes each designed to downregulate a different DZ-expressed gene or by
20 crossing together *B. napus* lines that individually are transformed with such transgenes. Such methods are complex either involving transformation with a construct containing multiple chimeric genes or require the maintenance of several transgenic loci in the breeding program. A preferred method is to transform with a chimeric gene consisting of a single promoter driving expression of an antisense or
25 partial sense transcript which is comprised of elements of all the DZ-expressed genes to downregulated. Similarly a single promoter could be used to drive the expression of multiple ribozymes each targeted against a different DZ-expressed gene. The use of a single promoter to drive expression of a combination of antisense, partial sense

and ribozymes is also possible. Ideally the promoter will be pod DZ-specific, however a useful promoter may be pod-specific or even constitutively active. A suitable DZ-specific promoter would be that of DZ2, DZ2B, DZ2AT3 or ESJ2A (WO 99/13089).

5

Accordingly, the present invention provides a nucleic acid sequence according to the first or second aspects (and also all aspects which include the first or second aspects) in combination with one or more further nucleic acid sequences which are dehiscence-zone expressed. Examples of such sequences include Sac66, DZ15 and
10 OSR(7), Figures 15-17 respectively. Such sequence may be in sense or in antisense orientation. Such a sequence may be included as full length genomic, full-length cDNA or partial sequences; the sequences may be as shown in the figures or may have the same sequence identity (both for aminoacid sequence and nucleic acid sequence) as described above for the protein according to the second aspect of the
15 invention or the nucleic acid according to the first or second aspects of the invention. As will be recognised by those skilled in the art a partial sequence may be useful in either the sense or antisense orientation.

The invention is described by reference to the enclosed drawings;

20

Figure 1 DZ2 full length sequence showing original PCR product and primer sites

Figure 2 Amino acid alignment with bacterial response regulator proteins &
25 *ETR1*

	Figure 3	Northern analysis of expression of DZ2 in pods and other tissues. The lower panel shows the ethidium bromide-stained RNA gel prior to blotting and probing with DZ2
5	Figure 4	Comparison of bacterial two-component systems with DZ2
	Figure 5	Sequence of the promoter region of B.napus DZ2B.
	Figure 6	Nucleic and putative peptide sequence alignments of DZ2 with DZ2B.
10	Figure 7	Northern analysis of expression of DZ2B in pods and other tissues. The probe was labeled DZ2B cDNA.
	Figure 8	Schematic diagram of pDZ2B-GUS-SCV
15	Figure 9	DZ2AT3 cDNA sequence showing the putative DZ2AT3 peptide.
	Figure 10	Amino acid alignment of DZ2AT3 with DZ2 and DZ2B.
20	Figure 11	Sequence of the promoter region of A.thaliana DZ2AT3.
	Figure 12	Schematic diagram of pDZ2AT3-GUS-SCV.
	Figure 13	Schematic diagram of pPGL-DZ2as-SCV and pDZ2B-DZ2as-SCV.
25	Figure 14	Schematic diagram of pWP357-SCV.
	Table 1	Pod shatter resistance of WP357-SCV transformants.

Figure 15 Nucleic acid sequence and putative amino acid sequence of Sac66.

Figure 16 Nucleic acid sequence and putative amino acid sequence of DZ15.

Figure 17 Nucleic acid sequence and putative amino acid sequence of OSR7 (9)

The present invention is now described with reference to the following, non-limiting examples.

Example 1- Isolation and characterisation of expression of DZ2

Plant Material

Seeds of *B. napus* cv Rafal were grown as described by Meakin and Roberts, (1990a) with the following modifications. Single seedlings were potted into 10cm pots, and after vernalization, were re-potted into 21cm pots. At anthesis tags were applied daily to record flower opening. This procedure facilitated accurate age determination of each pod. Pods were harvested at various days after anthesis (DAA). The dehiscence zone was excised from the non-zone material and seed using a scalpel blade (Meakin and Roberts (1990b)) and immediately frozen in liquid N₂ and stored at -70°C.

RNA Isolation

All chemicals were molecular biology grade and bought from either Sigma Chemical Ltd (Dorset, UK), or Fisons (Loughborough, UK). Total RNA was extracted using the polysomal extraction method of Christoffersen and Laties, (1982), with the following alterations. The plant material was ground to a powder in liquid N₂ and then in 10 volumes of extraction buffer (200mM Tris-acetate [pH 8.2], 200mM magnesium

acetate, 20mM potassium acetate, 20mM EDTA, 5% w/v sucrose, after sterilisation 2-mercaptoethanol was added to 15mM and cycloheximide added to a final concentration of 0.1 mg ml⁻¹). The supernatant was then layered over 8 ml 1M sucrose made with extraction buffer and centrifuged in a KONTRON™ (Switzerland) TFT 70.38 rotor at
5 45,000rpm (150,000g) for 2 hr at 2°C in a Kontron CENTRIKON™ T-1065 ultra-centrifuge. Pellets were then resuspended in 500µl 0.1M sodium acetate, 0.1% SDS, pH 6.0 and phenol/chloroform (1:1 v/v) extracted and the total RNA precipitated. Poly(A)⁺ RNA was isolated from total RNA extracted, from both the zone and non-zone tissue of 40, 45 and 50 DAA pods, using a Poly(A) QUIK™ mRNA purification kit
10 (Stratagene, Cambridge, UK) following the manufacturers instructions, and then bulked together. Total RNA was also extracted from leaves, stems, seeds and pods using a method described by Dean *et al*, (1985) for use in Northern analyses.

Differential display

15 This was performed essentially as described by Liang and Pardee (1992) using RNA extracted from 40 DAA pod dehiscence zones and non-zones. First strand cDNA copies of the RNAs (40 DAA DZ/NZ) were made using 50U M-MLV (Moloney Murine Leukemia Virus) reverse transcriptase (50U/µL) (Stratagene) in a 20µL
20 reaction containing 1x M-MLV buffer, 2.5mM dNTPs (Pharmacia), 1µg RNA, 30U RNase inhibitor (Promega) and 10µM oligo dT anchor primer 7 (5'-TTTTTTTTTTTTTGG-3'). The reaction conditions were as follows: 65°C for 5 minutes, 37°C for 90 minutes and 95°C for 5 minutes. Following first strand cDNA synthesis, 60µL dH₂O were added and the samples were either used directly for
25 PCR or stored at -20°C.

For PCR, 2µL cDNA were used as template in a 20µL reaction containing 1x PCR buffer, 1mM MgCl₂, 2µM dNTPs, 10µM oligo dT anchor primer 7 (5'-

TTTTTTTTTTTTTGG-3'), 2.5 μ M arbitrary primer A (5'- AGC CAG CGA A -3'),
0.5 μ L 35S-dATP (> 1000 Ci/mmol) (Amersham) and 1U *Taq* DNA polymerase
(5U/ μ L) (Gibco BRL). The thermocycling conditions were as follows: 40 cycles of
94°C for 30 seconds, 40°C for 2 minutes, 72°C for 30 seconds followed by 72°C for
5 minutes. The PCR products were fractionated on a 5% polyacrylamide/7M urea
gel after addition of 5 μ L loading buffer (95% (v/v) formamide, 20mM EDTA,
0.05% (w/v) xylene cyanol, 0.05% (w/v) bromophenol blue) to each sample.
Following electrophoresis the gel was dried at 80°C under vacuum for 1 hour then
exposed to X-ray film (BioMax-MR, Kodak) in a light tight cassette for 48 hours.
The dried gel and autoradiogram were aligned so that bands that appeared in the DZ
and not in NZ could be cut out and the DNA eluted according to Liang et al. (1995).
The eluted PCR products (4 μ L) were reamplified in a 40 μ L reaction containing 1x
PCR buffer, 1mM MgCl₂, 20 μ M dNTPs, 10 μ M oligo dT anchor primer 7 (5'-
TTTTTTTTTTTTTGG-3'), 2.5 μ M arbitrary primer A (5'- AGC CAG CGA A -3')
and 2U *Taq* DNA polymerase (5U/ μ L) (Gibco BRL) using the following
thermocycling conditions: 40 cycles of 94°C for 30 seconds, 40°C for 2 minutes,
72°C for 30 seconds followed by 72°C for 5 minutes. The resulting PCR product
was cloned into the TA cloning vector (Invitrogen) and sequenced (Figure 1). In
order to prepare an antisense strand-specific riboprobe, the PCR product was
subcloned into pBluescript (Stratagene).

Expression analysis and characterisation of DZ2

Northern analysis using an antisense strand-specific riboprobe to the DZ2 PCR
product, showed that DZ2 hybridised to a transcript of 0.6kb which is expressed in
the DZ of 20-50 DAA pods with a peak in expression at 40DAA. Minimal
expression was observed in the pod NZ [Figure 2]. A random-primed labelled DNA
probe (Stratagene) of the 330bp DZ2 PCR product (amplified using primers DZ2FL

and DZ2RL - see Figure 1) was used to screen a *B. napus* DZ cDNA library from which, following three rounds of screening to obtain pure plaques, a full length DZ2 cDNA (606bp) was obtained (Figure 1). An antisense strand-specific riboprobe of the full length DZ2 cDNA was hybridised to total RNA extracted from pod DZ/NZ (as in Figure 2), leaf abscission zones (AZ) and non-zones (NZ) (following exposure to 10 μ L/L ethylene for 72 hours), seed, root, flower and leaf. Figure 3 shows that DZ2 hybridises to a 0.6kb message which is present in the pod DZ at 20-50 DAA with maximum expression at 40DAA. Again there is minimal expression in pod NZ and no apparent expression of DZ2 in AZ, NZ, leaf, root, seed or flower RNA. By the sensitive technique of RT-PCR analysis DZ2 expression can also be detected in anthers and the funiculus, both tissues that contain dehiscent zones

The 606bp cDNA (DZ2) encodes a putative protein of 136 amino acids. Comparison of the DZ2 translated sequence to the OWL protein database [Bleasby and Attwood (1994)] showed low but consistent homology to a group of bacterial proteins comprising two-component regulatory systems. In particular, DZ2 possesses the conserved amino acid residues required for phosphorylation of the receiver domain of the response regulator component (see Figure 4). DZ2 plays a role in a signal transduction cascade resulting at least in one respect in pod shatter. It is therefore a good candidate for down-regulation of pod shatter processes using antisense technology. DZ2 is a novel plant protein in that independent proteins with homology to bacterial receivers are yet to be reported in plants.

The full length cDNA was excised from the pBluescript cloning vector by digestion with *Eco*RI and *Xho*I restriction enzymes (Gibco BRL). Following purification from a 1% agarose gel the 606bp cDNA was random primed labelled (Stratagene) and used to screen a *B. napus* genomic library in the BlueStar vector. Following three rounds of screening to obtain pure plaques, a single genomic clone was isolated

which carries a 15kb genomic DNA insert. The promoter of the DZ2 gene is isolated from this genomic clone using standard techniques (see Example 2).

Example 2 - Isolation and characterisation of the *B.napus* DZ2B promoter.

To obtain the *B.napus* DZ2 promoter a *B.napus* genomic library was screened with a labelled DZ2 probe. The full length cDNA was excised from the pBluescript cloning vector (Stratagene) by digestion with *Eco*RI and *Xho*I restriction enzymes (Gibco BRL). Following purification from a 1% agarose gel the 606bp cDNA was random primed labelled (Stratagene) and used to screen a *B. napus* genomic library in the BlueStar vector (Novagen). Following three rounds of screening to obtain pure plaques, a single genomic clone was isolated which carries a 15kb genomic DNA insert. The region hybridising to DZ2 was sequenced and found to encode a protein homologous to, but not identical to DZ2. This DZ2-like gene was designated DZ2B (Figure 5). The primers DZ2BFL (Figure 5) and T7 were used to PCR out a DZ2B cDNA from the *B.napus* DZ cDNA library.

5' AACCAAGTCAGTAGAAGTG 3' DZ2BFL

5' AATACGACTCACTATAGG 3' T7

The DZ2 and DZ2B cDNAs are 80% identical (according to the default parameters of the GAP computer program, version 6, Deveraux *et al.*, 1984, and available from the University of Wisconsin Genetics Computer Group (UWGCG)) at the nucleotide level in the region of overlap of the coding sequences (Figure 6a) and the putative proteins encoded by DZ2 and DZ2B are 80% identical (according to the default parameters of the GAP computer program, version 6, Deveraux *et al.*, 1984, and available from the University of Wisconsin Genetics Computer Group (UWGCG)) (Figure 6b). Sequence analysis of more DZ2 and DZ2-like cDNAs and Southern analysis shows that there are two DZ2 genes in *B.napus*, DZ2 and DZ2B,

each represented by 2 slightly different cDNAs. This is consistent with one gene being encoded by the *B.campestris* derived-genome and the other from the genome derived from *B.oleracea*.

- 5 RT-PCR with primers specific to DZ2B showed that DZ2B is only expressed in pods. This was confirmed by northern analysis which showed preferential expression in the DZ (Figure 7). Thus DZ2B has a similar pattern of expression as DZ2 and is thus a suitable source of a DZ-expressed promoter.
- 10 Primers DZ2BGenF and DZ2BGenR were used to PCR a 1253bp DZ2B promoter fragment (Figure 5).

5' GGCTCTAGACGAACTGCGGAGCAAGG 3' DZ2BGENF

5' CTGCCATGGTCGGTTTTTTTCTTCGAAC 3' DZ2BGENR

- 15 These primers introduced an XbaI site at the 5' end of the PCR fragment and an NcoI site around the initiating Met of DZ2B. Thus the PCR fragment was cloned as an XbaI, NcoI fragment between the XbaI and NcoI sites of pWP272 (WO 99/10389) forming pDZ2B-GUS. The chimeric pDZ2B-GUS-CaMV polyA gene
- 20 was then transferred as an XbaI, XhoI fragment between the XbaI and SalI sites of pSCV nos-nptII (WO 95/20668) forming pDZ2B-GUS-SCV (Figure 8). The pDZ2B-GUS-SCV binary vector was transferred to the agrobacterial strain pGV2260 and transformed *B.napus* plants produced by agrobacterial transformation essentially as described in Moloney M et al., (1989). Gus expression is observed in the pod DZ.

25

Example 3 - Isolation and characterisation of a DZ2 *Arabidopsis thaliana* homologue

To demonstrate that a DZ2 orthologous gene can be isolated from another plant species the functional equivalent of *B.napus* DZ2 / DZ2B was isolated from *Arabidopsis thaliana*. The *B.napus* DZ2 cDNA was used as a probe to screen an *Arabidopsis* cDNA library (J. Giraudat, ISV-CNRS, France). Figure 9 shows the sequence of a cDNA (DZ2AT3) that hybridised to the DZ2 probe. DZ2AT3 has 85% nucleic acid identity to DZ2 and 85% to DZ2B (according to the default parameters of the GAP computer program, version 6, Deveraux *et al.*, 1984, and available from the University of Wisconsin Genetics Computer Group (UWGCG)) in the coding regions which are common to all three sequences. The putative peptide encoded by DZ2AT3 has 80% identity to DZ2 and 80% to DZ2B (according to the default parameters of the GAP computer program, version 6, Deveraux *et al.*, 1984, and available from the University of Wisconsin Genetics Computer Group (UWGCG)) in the regions which are common to all three sequences (Figure 10). RT-PCR analysis of RNA isolated from leaves, roots, flowers and siliques showed that DZ2AT3 was specifically expressed in siliques. Southern hybridisation analysis showed that the DZ2AT3, DZ2 and DZ2B probes each identify a single identical band in *A.thaliana*. This indicates that *A.thaliana* contains one DZ2 gene in contrast to *B.napus* which contains two.

The Genome walker kit (Clontech) was used to isolate the DZ2AT3 promoter from *A.thaliana* genomic DNA. Nested PCR was performed using primer GW1 first, then AT3GW2 each in conjunction with the Genome Walker kit primer (Figure 9). Figure 11 shows the sequence of the promoter region of DZ2AT3 thus obtained. The primers ATDZ2F and ATDZ2R were used to PCR a 1195bp promoter fragment from the DZ2AT3 genomic sequence (Figure 11).

5' CACTAGTAGGGCACGCGTGGTCG 3' ATDZ2F
 5' TCCATGGTCGATTTCTTTTCTCTCAAG 3' ATDZ2R

These primers introduced an SpeI site at the 5' end of the PCR fragment and an
 5 NcoI site around the initiating Met of DZ2AT3. Thus the PCR fragment was cloned
 as an SpeI, NcoI fragment between the XbaI and NcoI sites of pWP272 (WO
 99/13089) forming pDZ2AT3-GUS. The chimeric pDZ2AT3-GUS-CaMV polyA
 gene was then transferred as a SalI, XhoI fragment into the SalI site of pSCV nos-
 nptII (WO 95/20668) forming pDZ2AT3-GUS-SCV (Figure 12). The pDZ2AT3-
 10 GUS-SCV binary vector was transferred to the agrobacterial strain pGV2260 and
 transformed *B.napus* plants produced by agrobacterial transformation essentially as
 described in Moloney M et al., (1989). Gus expression is observed in the pod DZ.

15 **Example 4 - Production of shatter-resistant *B.napus* plants by antisense
 downregulation of DZ2**

Downregulation of the DZ2 gene or reduction in DZ2 protein levels in the pod DZ
 will result in plants that are resistant (or more resistant than without this
 modification) to pod shatter. Standard techniques, commonplace in the art, such as
 20 the expression of antisense DZ2 mRNA, full sense mRNA, partial sense mRNA or a
 ribozyme directed against DZ2 mRNA are effective. Expression of these RNAs
 requires a promoter that is active in the pod DZ at the time at which DZ2 is
 expressed. Ideally the promoter will be pod DZ-specific, however a useful promoter
 may be pod-specific or even constitutively active. A suitable promoter would be that
 25 of DZ2. Although DZ2 is expressed in the anther DZ, pod DZ and funiculus DZ,
 DZ2 promoter -GUS fusion studies show that in different transformants the relative
 level of expression in these three sites is variable but is stability heritable. Thus
 some transformants are obtained in which expression is largely or exclusively

confined to the pod DZ. This suggests that the pDZ2 promoter is comprised of distinct elements each specifying expression in a particular DZ. Alternatively the site of transgene integration may influence relative expression levels in the DZ tissues. The DZ2 promoter is therefore linked to the DZ2 cDNA such that the DZ2 is in the antisense orientation forming pDZ2-antiDZ2. This chimeric gene is transferred to the binary vector pNos-NptII-SCV (W0 96/30529). This binary vector is transferred to the agrobacterial strain pGV2260 and transformed *B.napus* plants produced by agrobacterial transformation essentially as described in Moloney M et al., (1989) Plant Cell Reports 8, 238-242. A proportion of transformed *B.napus* plants exhibit reduced levels of DZ2 message and are resistant to pod shatter.

Example 5 - Production of shatter-resistant *B.napus* plants by antisense downregulation of DZ2

Downregulation of the DZ2 gene or reduction in DZ2 protein levels in the pod DZ will result in plants that are resistant to pod shatter. Techniques such as the expression of antisense DZ2 mRNA, full sense mRNA, partial sense mRNA or a ribozyme directed against DZ2 mRNA will be effective. Expression of these RNAs requires a promoter that is active in the pod DZ at the time at which DZ2 is expressed. Ideally the promoter will be pod DZ-specific, however a useful promoter may be pod-specific or even constitutively active. Although DZ2 / DZ2B is expressed in the anther DZ, pod DZ and funiculus DZ, DZ2B promoter -GUS fusion studies show that in different transformants the relative level of expression in these three sites is variable but is stably heritable. Thus some transformants are obtained in which expression is largely or exclusively confined to the pod DZ. This suggests that the pDZ2 promoter is comprised of distinct elements each specifying expression in a particular DZ. Alternatively the site of transgene integration may influence relative expression levels in the DZ tissues. Thus a suitable DZ-specific promoter would be that of DZ2, DZ2B, DZ2AT3 or ESJ2A (WO 99/13089).

The primers DZ2FLA and DZ2RLA were used to PCR a 349bp fragment from the DZ2 cDNA:-

5 5' GGCGAATTCCGGTGAGGAGGCAGTAATC 3' DZ2FLA
 5' GGCCCATGGCATAACATACACTTAGAC 3' DZ2RLA

The primers introduce an EcoRI and NcoI site at the ends of the DZ2 PCR fragment. To link the DZ2 PCR fragment in an antisense orientation to the promoter of ESJ2A (pPGL) the DZ2 PCR fragment was cloned as a NcoI, EcoRI fragment between the NcoI and EcoRI sites of pWP272 (WO 99/13089) forming pPGL-DZ2as. The pPGL-antisense DZ2 chimeric gene was transferred as a XbaI, XhoI fragment from pDZ2as into the XbaI and SalI sites of the binary vector pSCV nos-nptII (WO 95/20668) forming pPGL-DZ2as-SCV (Figure 13a).

The pPGL-DZ2as-SCV binary vector was transferred to the agrobacterial strain pGV2260 and transformed *B.napus* plants produced by agrobacterial transformation essentially as described in Moloney M et al., (1989). A proportion of transformed *B.napus* plants exhibit reduced levels of DZ2 and DZ2B message and were resistant to pod shatter

Similarly, to link the DZ2 PCR fragment in an antisense orientation to the promoter of DZ2B, the DZ2 PCR fragment is cloned as a NcoI, EcoRI fragment between the NcoI and EcoRI sites of pDZ2B-GUS forming pDZ2B-DZ2as. The pDZ2B-DZ2as chimeric gene is transferred as a XbaI, XhoI fragment from pDZ2B-DZ2as into the XbaI and SalI sites of the binary vector pSCV nos-nptII (WO 95/20668) forming pDZ2B-DZ2as-SCV (Figure 13b).

The pDZ2B-DZ2as-SCV binary vector is transferred to the agrobacterial strain pGV2260 and transformed *B.napus* plants. Again a proportion of transformed *B.napus* plants exhibit reduced levels of DZ2 and DZ2B message and are resistant to pod shatter.

5

Similarly a proportion of *B.napus* plants transformed with a pDZ23A-DZ2as-SCV construct exhibit reduced levels of DZ2 and DZ2B message and are resistant to pod shatter.

10 **Example 6 - Production of shatter-resistant *B.napus* plants by antisense downregulation of multiple DZ-expressed genes**

In addition to DZ2 several other DZ-expressed genes have been previously isolated and individually downregulated to result in *B.napus* plants that have increased resistance to pod shatter; namely Sac66 (WO 96/30529 Figure 15), DZ15 (Figure 16) and OSR 7(9) (Figure 17). It is anticipated that downregulation of more than one gene involved in pod shatter will further increase resistance to pod shatter. This could be achieved by combining different transgenes by transformation with several transgenes each designed to downregulate a different DZ-expressed gene or by crossing together *B.napus* lines that individually are transformed with such transgenes. Such methods are complex either involving transformation with a construct containing multiple chimeric genes or require the maintenance of several transgenic loci in the breeding program. A preferred method is to transform with a chimeric gene consisting of a single promoter driving expression of an antisense or partial sense transcript which is comprised of elements of all the DZ-expressed genes to be downregulated. Similarly a single promoter could be used to drive the expression of multiple ribozymes each targeted against a different DZ-expressed gene. The use of a single promoter to drive expression of a combination of

antisense, partial sense and ribozymes is also possible. Ideally the promoter will be pod DZ-specific, however a useful promoter may be pod-specific or even constitutively active. A suitable DZ-specific promoter would be that of DZ2, DZ2B, DZ2AT3 or ESJ2A.

5

Consequently the ESJ2A promoter was linked to a multiple antisense gene consisting of elements of Sac66, DZ2, DZ15 and OSR 7(9) in the following manner:- The original DZ15 PCR product in pCRII (Invitrogen) (see Figure 16) was cloned as an EcoRI fragment into pBluescript SK (Stratagene) forming pDZ15-BS, such that the DZ15 3' end is nearest the SstI site of the vector. T7 and DZ15RL primers were used to PCR a 456bp DZ15 fragment from pDZ15-BS which was cloned into the EcoRV site of pGEM5zf (Promega) forming pWP351, such that the DZ15 3' end is nearest the SphI site of the vector.

15 5' AATACGACTCACTATAGG 3' T7
5' AACAGCTGAAAACCTCACGAAG 3' DZ15RL

The EcoRI, NcoI fragment of pWP351 cloned between the EcoRI and NcoI sites of pDZ2-BS forming pWP356. pDZ2-BS consists of the DZ2 cDNA cloned as an EcoRI, XhoI fragment into pBluescript SK such that the 3' end is nearest the KpnI site of the vector. A 361bp Sac66 fragment was PCR'd from the Sac66 cDNA (WO 96/30529) using the primers F1 and RI which introduce NcoI and PstI sites into the ends of the PCR product.

25 5' GGCCCATGGCTGCCAAGCTTTGAGTAGC 3' F1
5' GGCCTGCAGTGCCTAGGATCTGGAAGC 3' RI

The Sac66 PCR product was cloned as an NcoI, EcoRI fragment between the NcoI and EcoRI sites of pWP272 (WO 99/13089) forming pWP288A. EcoRI DZ15+DZ2 and OSR 7(9) fragments from pWP356 and pOSR 7(9)-CRII were cloned into the EcoRI site of pWP288A such that DZ15+DZ2 and OSR 7(9) are in an antisense orientation with respect to PGL promoter. (pOSR 7(9)-CRII consists of the 306bp OSR 7(9) PCR fragment (see Figure 17) cloned into pCRII (Invitrogen)). The chimeric pPGL-antisense Sac66+DZ2+Dz15+OSR 7(9) gene was transferred as a XbaI, XhoI fragment into the XbaI and SalI sites of the binary vector pSCV nos-nptII (WO 95/20668) forming pWP357-SCV (Figure 14). The pWP357-SCV binary vector was transferred to the agrobacterial strain pGV2260 and transformed B.napus plants produced by agrobacterial transformation essentially as described in Moloney M et al., (1989) Plant Cell Reports 8, 238-242.

Resistance to podshatter was measured using an impact pendulum device (Liu X-Y, Macmillan RH and Burrow RP 1994 Journal of Texture Studies 25_p179-189) (Table1). The mean energy values shown in Table 1 represent the energy required to rupture the pod on impact with the pendulum. These values are an average from measurements of 20 mature pods. The letters A to L indicate grouping of transformants with significantly different podshatter resistance (ie Group A is significantly different from B when analysed by ANOVA using a Fisher PLSD analysis with a significance level of 95% (Statview 512+). Lines with a number of letters are not significantly different from other lines sharing the same letter. The results shown in Table 1 indicate that 24 lines exhibited significantly higher resistance to podshatter than non-transformed controls whilst 17 lines were not significantly different from the control. The degree and frequency of pod shatter resistance achieved with pWP357-SCV was greater than that obtained by transformation with constructs that downregulate a single DZ-expressed gene.

REFERENCES

- 5 1. Bleasby A J and Attwood T K, OWL – A Non-redundant Composite Protein
Sequence Database. Nucleic Acid Research 22:3574-3577 (1994)
2. Christoffersen and Laties, Proc. Natl. Acad. Sci. 79, 4060-4063 (1982)
- 10 3. Dean *et al.*, EMBO J. 4: 3055-3061 (1985)
4. Deveraux *et al.*, Nucl. Acids Res. 12:387 (1984)
5. Hocking P J and Mason L: Accumulation, distribution and redistribution of
15 dry matter and mineral nutrients in fruits of canola (oilseed rape) and the
effect of nitrogen fertiliser and windrowing. Australian Journal of
Agriculture Research 44: 1377-1388 (1993)
6. Hakwa *et al.*, Science 198:105-63 (1977)
- 20 7. Jenkins *et al.*: 5th International Conference of Plant Molecular Biology,
Abstract 310 (1997)
8. Johnson-Flanagan AM and Spencer MS: Ethylene production during
25 development of mustard (*Brassica juncea*) and canola (*Brassica napus*) seed.
Plant Physiol 106: 601-606 (1994)
9. Liang P and Pardee A: Differential display of eukaryotic messenger RNA by

means of the polymerase chain reaction. Science 257: 967-971 (1992)

- 5
10. Laing P, Bauer D, Averboukh L, Warthoe P, Rohrwild M, Muller H, Strauss M, Pardee A B: Analysis of altered gene expression by differential display. Methods in Enzymol 254: 304-321 (1995)
11. Meakin P J and Roberts J A: Dehiscence of fruit in oilseed rape (*Brassica napus* L.): anatomy of pod dehiscence. J Expt. Bot 41: 995-1002 (1990a)
- 10 12. Meakin P J and Roberts J A: Dehiscence of fruit in oilseed rape (*Brassica napus* L.): the role of cell wall degrading enzymes and ethylene. J Expt. Bot 41: 1003-1011 (1990b)
- 15 13. Moloney M *et al*; Plant Cell Reports, 8, 238-242 (1989)
14. Needleman and Wunsch J. Mol. Biol. 48:443 (1970)
15. Smith and Waterman Adv. Appl. Math 2: 482 (1981)

CLAIMS

1. Nucleic acid encoding a signal transduction protein involved in the process of dehiscence.
- 5
2. Nucleic acid as claimed in claim 1 wherein the process involves the production of a hydrolytic enzyme.
3. Nucleic acid as claimed in claim 1 or claim 2 which is naturally expressed in a dehiscence zone.
- 10
4. Nucleic acid encoding a protein wherein the protein:
- a) comprises the amino acid sequence shown in Figure 1 or;
- 15
- b) has one or more amino acid deletions, insertions or substitutions relative to a protein as defined in a) above and has at least 40% amino acid sequence identity therewith; or
- 20
- c) is a fragment of a protein as defined in a) or b) above, which is at least 10 amino acids long.
5. Nucleic acid as claimed in any one of claims 1 to 4 which comprises the sequence set out in Figure 1 or a fragment thereof which is at least 30 bases long.
- 25
6. Nucleic acid, as claimed in any one of claims 1 to 5 in combination with one or more further nucleic acid sequence which is dehiscence-zone expressed.

7. Nucleic acid which is antisense to nucleic acid as claimed in any one of claims 1 to 6.
- 5 8. Nucleic acid as claimed in any one of claims 1 to 7 including a promoter or other regulatory sequence which controls expression of the nucleic acid.
9. Nucleic acid which is the naturally occurring promoter or other regulatory sequence which controls expression of nucleic acid as claimed in any one of claims 1 to 8.
- 10 10. Nucleic acid as claimed in any one of claims 1 to 9 which is in the form of a vector.
- 15 11. A cell comprising nucleic acid as claimed in any one of claims 1 to 10.
12. A plant cell as claimed in claim 11.
13. A process for obtaining a cell as claimed in claim 11 or claim 12 comprising introducing nucleic acid as claimed in any one of claims 1 to 10 into said cell.
- 20 14. A plant or a part thereof comprising a cell as claimed in claim 11 or claim 12.
- 25 15. Propagating material or a seed comprising a cell as claimed in claim 11 or claim 12.

16. A process for obtaining a plant or plant part as claimed in claim 14 or claim 15 comprising obtaining a cell as claimed in claim 11 and growth thereof or obtaining a plant, plant part, or propagating material as claimed in claim 14 or claim 15 and growth thereof.
- 5
17. A signal transduction protein involved in the process of plant dehiscence.
18. A protein which:
- 10
- a) comprises the amino acid sequence shown in Figure 1 or;
- b) has one or more amino acid deletions, insertions or substitutions relative to a protein as defined in a) above, and has at least 40% amino acid sequence identity therewith; or
- 15
- c) a fragment of a protein as defined in a) or b) above which is at least 10 amino acids long.
19. A protein as claimed in claim 17 or claim 18 which is isolated or
- 20
- recombinant.
20. A process for regulating/controlling dehiscence in a plant or a part thereof, the process comprising obtaining a plant or part thereof as claimed in claim 14.
- 25
21. A process as claimed in claim 20 which comprises obtaining a plant cell as claimed in claim 21 or part of a plant as claimed in claim 14 and deriving a plant therefrom.

22. A process as claimed in claim 20 which comprises obtaining propagating material or a seed as claimed in claim 15 and deriving a plant therefrom
23. A process as claimed in claim 20 wherein the dehiscence is of a pod or of an anther.
24. Use of nucleic acid as claimed in any one of claims 1 to 10 in the regulation/control of plant dehiscence.
25. Use of nucleic acid as claimed in any one of claims 1 to 10 as a probe.
26. Use of nucleic acid as claimed in any one of claims 1 to 10 in the production of a cell, tissue, plant part thereof or propagating material.
27. Nucleic acid comprising one or more of the underlined sequences as set out in Figure 1, or one or more of the primer sequences in Figure 5, 9 and/or 11.
28. Use of the nucleic acid as claimed in claim 27 as a PCR primer.
29. Use of a protein as claimed in any one of claims 17 to 19 as a probe.

Pub. No. 6294563

69/132

WO 99/49046

09/646679

PCT/GB99/00905

1/27

FIG. 1

NUCLEIC ACID AND PREDICTED PROTEIN SEQUENCE OF DZ2

1 GGCACGAGCAGAATCGAAGATGGCAACAATAATCCATGGGAGATATCGAGAAATAAGAA 60
M A T K S M G D I E K I K K

61 GAACTAAACGTGTGATCGTCGATGATGATCCACTAAACCTTATAATTCATGAGAAGAT 120
K L N V L I V D D D P L N L I I H E K I

121 CATCAAAGCGATTGGGGTATTTACACAGACAGCGAATAACGGTGAGGAGGCAGTAATCAT 180
I K A I G G I S Q T A N N G E E A V I I
↓ DZ2FL→

181 CCACCGTGACGGCGGCTCATCTTTTGACCTTATCCTAATGGATAAAGAAATGCCCGAGAG 240
H R D G G S S F D L I L M D K E M P E R

241 GGATGGTGTTCGACAACCTAAGAAGCTAAGAGAAATGGAAGTGAAGTCAATGATTGTTGG 300
D G V S T T K K L R E M E V K S M I V G

301 GGTGACTTCACTGGCTGACAATGAAGAGGAGCGCAGGGCTTTTCATGGAAAGCTGGACTTAA 360
V T S L A D N E E E R R A F M E A G L N

2/27

```

361 CCATTGCTTGGCAAAACCGTTAACCAAGACAGATCATCCCTCTCATTAACCAACTCAT 420
    H C L A K P L T K K D K I I P L I N Q L M
421 GGATGCTTGATGGATATATTTATATTATGGAACACACACATAATAACGCTAAGTGTG 480
    D A *
481 TATGTATGCATAGATACTTGCATGTGTGTTTAGAATTAGGGTTCTTTATCGTCCGT 540
    HindIII
541 GATATATAATCATGTAAGTTGTTGCTTTAAGCTTATAAAATATTAAAGGGTTTCCT 600
601 CTACC

```

The primer sites for DZ2FL and DZ2RL are underlined, as are the recognition sequences for *NcoI* and *HindIII* restriction enzymes. Shown in bold are the conserved amino acid residues required for phosphorylation. The extent of the original PCR product isolated by differential display is shown by ↓.

FIG. 1 CONT'D

3/27

Alignment of the predicted protein sequence of DZ2 with those of
bacterial response regulator proteins.

	1				50
DZ2	MATKSMGDIE	KIKKKLNVLI	VDDDPLNLII	HEKIIKAIG.	GISQTANNGE
OMPRMQENYKILV	VDDDMRLRAL	LERYLTEQGF	.QVRSVANAE
PHOBMARRILV	VEDEAPIREM	VCFVLEQNGF	.QPVEAEDYD
NTRCMQRGIVWV	VDDDSSIRWV	LERALAGAGL	.TCTTFENG
SPOOFMMNEKILI	VDDQYGIRIL	LNEVFNKEGY	.QTFOAANGL
CHEY	MADKELKFLV	VDDFSTMRRI	VRNLLKELGF	NNVEEAEDGV
ETRLKVLV	MDENGVSRMV	TKGLLVHLGC	EVTTVSSNEE
	51				100
DZ2	EAVIIHRDGG	SSFDLILMDK	EMPERDGVST	TKKLREMEVK	SM..IVGVTS
OMPR	QMDRLLTR..	ESFHLMVLDL	MLPGEDGLSI	CRRLRSQS..	NPMPIIMVTA
PHOB	SAVNQLNE..	PWPDILLDW	MLPGGSGIQF	IKHLKRESMT	RDIPVVMLTA
NTRC	EVLAALAS..	KTPDVLLSDI	RMPGMDGLAL	LKQIKQ..RH	PMLPVIIMTA
SPOOF	QALDIVTK..	ERPDLVLLDM	KIPGMDGIEI	LKRMKV..ID	ENIRVIIMTA
CHEY	DALNKLQA..	GGYGFVISDW	NMPNMDGLEL	LKTIRADGAM	SALPVLMTA
ETRCLRVS	HEHKVVFMDV	CMPGVENYQI	ALRI.....	.HXPLLVALS
	101				150
DZ2	LADNEEERRA	FMEAGLNHCL	AKPLTKDKII	PLINQLMDA.
OMPR	KGEEVDRIVG	.LEIGADDYI	PKPFNPPELL	ARIRAVLRRQ	ANELPGAPS.
PHOB	RGEEEDRVRG	.LETGADDYI	TKPFSPKELV	ARIKAVMRRI	SPM.....
NTRC	HSDLDAAVSA	.YQQGAFDYL	PKPFDIDEAV	ALVERAISHY	QEQQQPRNIE
SPOOF	YGELDMIQES	.KELGALTHF	AKPFDIDEIR	DAVKKYLPLK	SN.....
CHEY	EAKKENIIAA	.AQAGASGYV	VKPFTPATLE	EKLNKIFEKL	GM.....
ETR	GNTDKSTKEK	CMSFGLDGLV	LKPVSLDNIR	DVLSDLL...
	151				
DZ2				
OMPR	OmpR =	<i>E. coli</i>	(Involved in osmoregulation)	
PHOB	PhoB =	<i>E. coli</i>	(Involved in phosphate utilisation)	
NTRC	VNGP	NtrC =	<i>S. typhimurium</i>	(Involved in nitrogen utilisation)	
SPOOF	SpoOF =	<i>B. subtilis</i>	(Involved in sporulation)	
CHEY	CheY =	<i>E. coli</i>	(Involved in chemotaxis)	
ETR	ETR =	<i>A. thaliana ETR1</i>	gene encoding an ethylene receptor (partial amino acid sequence)	

The predicted protein sequence of DZ2 is shown in bold as are the conserved amino acid residues required for phosphorylation of the protein

FIG. 2

4/27

Expression analysis of DZ2 in various plant organs using Northern




FIG. 3

5/27

Comparison of bacterial two-component regulatory systems with DZ2



Bacterial two-component system***Arabidopsis thaliana* ETR1 gene*****Arabidopsis thaliana* ERS gene****DZ2**

FIG. 4

FIG. 5

6/27

TATATAAATACGGTTTAACAGATATGTTCTGGTTATATAAATGTAATTCNATGTGCCNNTCAANTTTTATTTTATTTNATTTNGT 78

TNTACTAGGGACATTAGTTTTTAACNTTTTATATATCATGTAACAAAAAATAACNTTTTATATNTCAACTATGA 156

GCAATTATTCTTATAGTGTCTTTTCCAGAAATTTGACGACAACTTAACAAATTAATTTTGACGTTAGTT 234

AAGTAATTTTATATAGATGGATAAATTGAGCAAGCACATTACGAACTGCGGATCAAGGAGAGTCACAATTTAATCTTA 312

GGCTCTAGACGAACTGCGGAGCAAGG -> DZ2BGENF

XbaI

CGTTATACACAAAAATTATCTAAATACTATATATATATACAGCTGCATGCTACGATAATGATCAAAATGTTTATGTACTT 390

TTCAGCGAAAAATTCITTTGTGCGCCATACATTACTGTGTTAATGAATCATTAATAATGTGAAGGAGGAAAGAGTACAAAA 468

GGAGTTTTGTGAGGCAITTCGCAGACACTGAAATGTGAATAATAATAAGGAATTCGCCAATTTGATTTCTAGTTGGT 546

GAAGTGGTGAAAAATTGTATGTCCATTGCTTATAAACTATAAAATATAATATNTTNATATTATCACCINIGGACATTAG 624

TNNGATAGACCCCTAGCTAAAAATTTTTTAAAAATTATACATTCTATTTCTTNAAGTACCAAACTTAATTATCACAAATCGGA 702

TAAAAATTGTTTAAGAAACCATTAACAACTCAGCTTGTGGACTCTGAGAGAAACTAAGAGCTAGACATACGGTTAGTAG 780

TGTAGCCGCATTTTTTATGCTTAATTTGCTTAAGCATGACTTCTATGCTCCTTGAUGATATTTTATTTAATATCCCTAG 858

GACATATGGATTTGATAAAGATCTTTATCAACCTTTTCAACAGACCATTAGCTCAACAAACAAATACTGAAAGTATAT 936

7/27

```

AATCTTGGTTACAGAATCTTTATGCCAAAATATCATATATATAGAAATTCGGTTATGATTAAGATGAATTAATTTA 1013
ATTAATATATTTTTTCACCTTTTGTGTTTCTTATGTAATCTTAGTATTTGTTACACCATATGACCGAATTCGGTGTCATATTA 1092
GTTTGGTAAGACAACACTCAGTTGCAACGATGCAGATTACATTTTCAGGAAGATTCTATGTAAGAAAGATATTTCCGCTTTGT 1170
GGTGTGAAAATATGCCTCTTTTCACCTTTTTTTTCAACTATAAATTTTCGATCGATGTATCTACGTTCTTAACACAAATTCAC 1248
AATCTTCTTTTAGAATCCAAAATTTGTAAGCCGCTTTCTAATCTCTTTCTCAGTATACATATGTAATATGTATGCATATA 1326
TTATTATTTCATAATACAAACACGAACCCATGCAATGCAAGAAAGATAGTTACACGCTCATATAACAAACACAAAAAACATA 1404
CGCATGCATTAGAACACCTTGTATGTTAATTTCCATAAATGTTTTCGATAAACATTTCTTCGTTTAAATTAGCTTCTTTT 1482

NcoI
<- GTTCGAAGAAAAAACCGACCATGGCAG DZ2BGENR AACCAAG
GTGTGAAGATTGTTCGAAGAAAAAACCGAAGATGGCAACAACGTCACATCCACGGGAGATATCAAGAAAAACCAAG 1560
M A T T S T S T G D I K K T K

TCAGTAGAAGTG -> DZ2BFL
TCAGTAGAAGTGGAAGAAACTTAACGTGTGTGATCGTTGATGATGATACAGTAATTCGTAAACTTCACGAGAATATC 1638
S V E V K K L N V L I V D D T V I R K L H E N I
ATCAAATCGATCGGTGGAATTTTCACAGACGGCTAAGAACGGTGAGGAGGCAGTGAACATCCACCGCGACGGCAATGCA 1716
I K S I G G I S Q T A K N G E E A V N I H R D G N A ->

```

FIG. 5 CONT'D

8/27

A) Dz2B cDNA sequence (top) -
Dz2 sequence (bottom)

FIG. 6

GGCAGGAGCAGAAATCGAAGATGGCAACAATCCATGGAGATATCGAGAAATAAAGAAGAACTAAACGTTGATCGTC
TCGTCNAT
10 20 30 40 50 60 70 80

GATGATCCTGTAAATACGTAACTTCACGAGATTATCATCAAAATCAATCGGTGGA---ATTTCACAGACAGCTAAGAACGGTG
.....
GATGATGCCACTAAACCTTATAATTCTGAGAGATCATCAAAAGCGATTGGGGGTATTTCACAGACAGCGGAATAACGGTG
90 100 110 120 130 140 150 160

AGGAGGCAGTGAACATCCACCGGACGGCAATGCATCTTTCGACCTTATCCTAATGGATAAGAAATGCCCGAGAGGGATGG
.....
AGGAGGCAGTGAATCATCCACCGTGACGGCGGCTCATCTTTTGACCTTATCCTAATGGATAAGAAATGCCCGAGAGGGATGG
170 180 190 200 210 220 230 240

ACTTTCGGCAACTAAGAAGCTAAGAGAAATGAAAGTGACGCTATGATTTATGGGGTGACGACACTGGCTGACAATGAAGAG
.....
TGTTTCGACAACTAAGAAGCTAAGAGAAATGGAAGTGAAAGTCAATGATTGTTGGGGTGACTTTCACCTGGCTGACAATGAAGAG
250 260 270 280 290 300 310 320

9 / 27

[illegible]

FIG. 6 CONT'D

60 | KK ... KK | 80

570
|
AAA

B) D22B peptide sequence (top) -
D22 peptide sequence (bottom)

60 | KK ... KK | 80


110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928

FIG. 6 CONT'D

11/27

FIG. 7

NORTHERN ANALYSIS OF EXPRESSION OF
DZ2B IN PODS AND OTHER TISSUES



DZ = POD DEHISCENCE ZONE (20 - 06 daa)

NZ = POD NON-ZONE

AZ = ABSCISSION ZONE

F = FLOWER

L = LEAF

R = ROOT

S = SEED

pDZ2B-GUS-SCV



FIG. 9

ATATATGTGATACAGATACATCTATATACAAATTAACACGAAACCATACATGACGGTGTGATCACACACGCACACA 78

CATAGAAACATAAACACGCAATAATTCTATACAGTTAATTTCATTTTAACTTACTTCTTTTGTGGAAGAT 156

TCTTGAGAGAAAAGAAATCGAAGATGGCAACAAAATCCACCGAGGTACCGAGAGAAAACCAAGTCGATAGAAAGTGAAGA 234
M A T K S T G G T E K T K S I E V K K

AGAAACTAATCAACGTGTTGATCGTATGATCCATTAAACCGTAGACTCCACGAGATGATCATCAAAACGATCG 312
K L I N V L I V D D D P L N R R L H E M I I K T I G
<- CGATCG

<- CGAATAACGGTGAGGAGGCATTAAATCA GW1
GAGGAATTTCTCAGACTGCAA AT3GW2
GAGGAATTTCTCAGACTGCAAAGAATGCGGAAGAGGCGNGTGATCCTCCACCGTGACGCGGAAGCATCTTTCGACCTTA 390
G I S Q T A K N G E E X V I L H R D G E A S F D L I

TTCTAATGGATAAGGAAATGCCTGAGAGGGATGGAGTTTCGACAATTAAGANGCTAAGAGAAATGAAAGGACGTCAA 468
L M D K E M P E R D G V S T I K X L R E M K G T S M

TGATCGTTGGGGTAACGTGAGTAGCTGACCAAGAAGAGCGTAAGGCTTTTATGGAAGCTGGGCTCAACCATGCT 546
I V G V T S V A D Q E E E R K A F M E A G L N H C L

TGGA AAAACCCCTTAACCAAGGCCAAGATCTTCCCGCTCATTAGCCACCTCTTCGATGCTTGATGGATGAAGGCTCATT 624
E K P L T K A K I F P L I S H L F D A .

AATGTATCTATAATTTCAATCATGAATCACCTACACGTGTATTTGACACAAAAATCTGCATTTGTGTATATAGGG 702

TTTCTCATATCTATGTTTGATTTATTTTCTTATCGTCCGAGGTAAATCATGCAAGTCATTTCTTTTGGCTAATAAAA 780

TATTAAAAATAAGGTTTCTCAAAAAAATAAAAAA

FIG. 9 CONT'D

16/27

B) DZ2A13 peptide sequence (top)
DZ2B peptide sequence (bottom)

MATKSTGGTEKTSIEVKKKLINVLIVDDPLNRRRLHEMIITIGGISQAKNGEEXVILHRDGEASFDLILMDKEMPERDG

 VXDDPVIRKLHEIIKSIIGGISQAKNGEEXVILHRDGEASFDLILMDKEMPERDG

VSTIKKLREMGTSMI VGVTSVADQEEERKAFMEAGLNHCLEKPLTKAKIFPLISHLFDA
 |
 LSATKKLREMGTSMI IGVTTLADNEEERKAFMEAGLNHCLEKPLSKAKILPLINNLMDA

FIG. 10 CONT'D

FIG. 11

GTAAATGCGACTCACTATAGGACGCGTGGTCGACGGCCCGGCTGGTCCTCATTCGTATTTGGCCCAATGGGCTACT 78
CACTAGTAGGCACGCGTGGTCG -> ATDZ2F
 SpeI
 AAAACAGTTTCACGATTGTTTTTTTTTTTTTTTAAATTTTAAACATGTATGTGGGATATTTTGGCTATAAAATTATG 156
 TAAAAAATTCACGATAGATTGTTGAATTTTGAATTTTCGAGTTAAATAATCTTCAAAATTACCTCACATTTACAAAAA 234
 GGTAAGAACTGTTGAAAAAATAATGCTCTATATAAAACACTAGACAATAACAAAAATACGTAATGCGTAAGAACCTAAATT 312
 ATGATTTTATTATCTTTCTTCCTTTTTTCCGTGAGTATAAGCCATTTTTCATAGTAAAGCAATTACGAATACGACATTG 390
 AACACTACTGACATATAAAGTAGTAGATTTTTGATGGGTAACTTTGTATGCTTAATTTGCTTAAGCATGAACCTCAATG 468
 CTTTATAAAAGTACTTCATGAGAAATATTCCTCGTTCTATACCTAGCAGAGGGTTCGATAGTGATTTTACAACCGTTC 546
 AACAAAAACCTTTAAACCCAAAAAACCAAGAATGAAAGTATCTAAACTTGATTATACATTTTCTTGTCTAAATTATCAA 624
 ATAACATACTCTCTTTTGTGTTTACTTATAAACGATATGAAAGAAATAAATAAAAGAACATAGAAATCTTTATTATGATCT 702

17/27

18/27

AGAAGAAATTAAAGAAATATATATATATTTTTTTCATTTCTACTCATGTTTCTTATACATTTCTTTAAATTTGTT	780
CACCATTTTGATTTACTTGTTCATATATTAGTTTGTATACAACTCACTTAGAATAATGTAGATTACATTTTCAGCCAA	858
ATTTCATGTAAAAGATGCTTTTCTTTTGTGATGTTTTTAAATGCTTTCTTTTTCACATTTTTTTTCTTTTAACTATAAAT	936
CTTGATCGAAATGCCCTACCTTCTTAGAACATAAGATCTTCTTTTAAATCCAAATCGTAGGCCACTATTTTCATTATACT	1013
TATGTAATATATGTGATACAGATACATNTATATACAAATTAACACGAAACCATACATGCACGGTGTGATCACACACG	1092
CACACACATAGAAACATAAACACACGCAATAATTTCTATACAGTTTAAATTTTCATTTTAACTTACTTCTTTTCTTTTGGT	1170

NcoI	
<- CTTGAGAGAAAAGAAATCGACCATGGA	
GAAGATTCTTGAGAGAAAAGAAATCGAAGATGGCAACAAAATCCACCGAGGTACCGAGAAAACCAAGTCGATAGAAG	1248
M A T K S T G G T E K T K S I E V	
TGAAGAAGAAACTAATCAACGTGTTGATCGTCGATGATCCATTAACCGTAGACTCCACGAGTGTCAATCAAAA	1324
K K K L I N V L I V D D D P L N R R L H E C H Q ->	

FIG. 11 CONT'D




FIG. 12




FIG. 13A

21 / 27




FIG.13B




FIG.14

FIG. 15

GGCATCAGGAGGTACCCGTAATAATCCACCATACAACAAAGTTCTGTGAAAGTCTCCCAA 60

AAACTGCAAGAGTCTCATATTAGTTCTTACTCTCAGAAATAAACACAGTGTTCCTGAA 120

AAGATTAGCGTTTCAAACCCCGAAATGGCCCGTTGTCATGGAAGTCTTGCTATTTTCTTA 180

M A R C H G S L A I F L 12

TGCGTTCTTTTGATGCTCGCTTGCTGCCAAGCTTTGAGTAGCAACGTAGATGATGGATAT 240

C V L L M L A C C Q A L S S N V D D G Y 32

GGTCATGAAGATGGAAGCTTCGAAACCGATAGTTTAATCAAGCTCAACAACGACGACGAC 300

G H E D G S F E T D S L I K L N N D D 52

GTTCTTACCTTGAAAAGCTCCGATAGACCCCACTACCGAATCATCAACTGTTAGTGTTCG 360

V L T L K S S D R P T T E S S T V S V S 72

AACTTCGGAGCAAAAGGTGATGGAAAACCGATGATACTCAGGCTTTCAAGAAAGCATGG 420

N F G A K G D G K T D D T Q A F K K A W 92

AAGAAGGCATGTTCAACAAATGGAGTGACTACTTTCTTGATTCTCTAAAGGGAAGACTTAT 480

K K A C S T N G V T T F L I P K G K T Y 112

CTCCTTAAGTCTATTAGATTCAGAGGCCCATGCAAAATCATACGTAGCTTCCAGATCCTA 540

L L K S I R F R G P C K S L R S F Q I L 132

GGCACTTTATCAGCTTCTACAAAACGATCGGATTACAGTAATGACAAGAACCCTGGCTT 600

G T L S A S T K R S D Y S N D K N H W L 152

24/27

ATTTGGAGGACGTTAATAATCTATCAATCGATGGCGGCTCGGCGGGGATTTGTTGATGGC 660
I L E D V N N L S I D G G S A G I V D G 172

AACGGAAAAATCTGGTGCAAACTCATGCAAAATCGACAAATCTAAGCCATGCACAAAA 720
N G K I W Q N S C K I D K S K P C T K 192

CGCCCAACGGCTCTTACTCTCTACAAACCTAAACAATTGGAATGTGAAGAACTCTGAGAGTG 780
A P T A L T L Y N L N L N V K N L R V 212

AGAAATGCACAGCAGATTTCAGATTTCGATTGAGAAATGCAACAGTGTGATGTTAAGAAT 840
R N A Q Q I Q I S I E K C N S V D V K N 232

GTTAAGATCACTGCTCCTGGCGATAGTCCCAACACGGATGGTATTCAATATCGTTGCTACT 900
V K I T A P G D S P N T D G I H I V A T 252

AAAAACATTGCAATCTCCAATTCAGACATTGGGACAGGTGATGATGCATATCCATTGAG 960
K N I R I S N S D I G T G D D C I S I E 272

GATGGATCGCAAAATGTTCAAAATCAATGATTTAACTTGGCGCCCGGTCAATGGCATCAGC 1020
D G S Q N V Q I N D L T C G P G H G I S 292

ATTGGAAGCTTGGGGATGACAAATTCCAAAGCTTATGTATCGGGAATTAATGTGGATGGT 1080
I G S L G D D N S K A Y V S G I N V D G 312

FIG. 15 CONT'D

25/27

GCTACGCTCTCTGAGACTGACAATGGAGTAAGAAATCAAGACTTACCAGGGAGGGTCAGGA 1140
A T L S E T D N G V R I K T Y Q G S G 332

ACTGCTAAGAACATTAAATTCCAAACATTCGTATGGATAATGTCAAGAATCCGATCATA 1200
T A K N I K F Q N I R M D N V K N P I I 352

ATCGACCAGAACTACTGCGACAGGACAAATGCGAACAACAAGAAATCTGCGGTTCAAGTG 1260
I D Q N Y C D K D K C E Q Q E S A V Q V 372

AACAATGTCGTCTATCGGAACATACAAAGGTACGAGCGCAACGGATGTGGCGATAATGTTT 1320
N N V V Y R N I Q G T S A T D V A I M F 392

AATTGCAGTGTGAAATATCCATGCCAAGGTATTGTGCTTGAGAAATGTGAACATCAAAGGA 1380
N C S V K Y P C Q G I V L E N V N I K G 412

GGAAAAGCTTCTTGCAAAAATGTCAATGTTAAGGATAAAGGCACCGTTTCTCCTAAATGC 1440
G K A S C K N V N V K D K G T V S P K C 432

CCTTAATTACTAAGTTGATTATGTAATATACATAAATACGTATTATATGTGGTTATAGAT 1500
P 433

GCCATCTATATCCTTATCTACGTATTGATTCTCGATATATATAGAAAACCTAAGGATTAT 1560

GGGAATATACATACAATAGTTGAGATAAATGTTGCTTGTATATGGTTCACCTGAAGTTGA 1620

TTGCTTGTCACGAATAAATGAATAATGTCATTGTC 1657

FIG. 15CONT'D

26/27

aggtgaccggttgctgatggcaatgtgctgggtcaagcgagaggtagacgggtggcttggaga
V T V A D G N V L V K R E V D G G L E T
cagttaaagtcaaattgccagctgtcattagcgccgacttgcggtcaatgagccgcggt
V K V K L P A V I S A D L R L N E P R Y
acgctactctgccccaatatcatgaaggccaagaagaagcccatcaaaaagctcacagcca
A T L P N I M K A K K K P I K K L T A T
cagatgtcgggtgtggacttggcgccacgtcaacaagtgttgagcgtagaagacccgccca
D V G V D L A P R Q Q V L S V E D P P T
ccagacaggctggttccattgtgcctgatgtcgacactctcatcaccaagttgaaagaaa
R Q A G S I V P D V D T L I T K L K E K
agggtcatttgtaatgcaatgtcaccaatacagttgttttagttcttaciaaattcttcgt
G H L *
gaggttttcagctgttaccaataatatTTTTTcaaaatcgattttattttacttgtaatt

taaaagatcaaataattaatacaatgaacatttttgtaacagcaatcttttttttatattt

tgagattttcatcgacttatgtcataattatttttatcaatttattgttggttgtagtg

atataataaagtatgttttctgggtcaaaa

FIG. 16

Year	1960	1961	1962	1963	1964	1965	1966	1967	1968	1969	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1960	1961	1962	1963	1964	1965	1966	1967	1968	1969	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	

5'
ggttgggtcgaaccataggtggaaaagcttcttctctctcgcttgacaaaatcctcttggtt
L G R T I G G K L L S L S L D K S S G S
.
cgggttttcagtcgccatcaggagtttctctatggtaaaagctgaggttcaaatgaaaacttg
G F O S H Q E F L Y G K A E V O M K L V
.
tcctggtaactctgtggaacagtcacaacattcttatcttaaatcaccgggaaactacat
P G N S A G T V T T F Y L K S P G T T W
.
gggatgagatcgatttcgagttcttgggaaacataaagtggccatccctatactctccata
D E I D F E F L G N I S G H P Y T L H T
.
ctaatgtttacacacgaaggctctggagacaaagaacagcagtttcattctatgggttcgac
N V Y T R R L W R Q R T A V S S M V R P
ccgacc 3'
D

FIG. 17

POWER OF ATTORNEY FROM ASSIGNEE

Biogemma UK Limited, a corporation of Great Britain, having a principal place of business at 200 Science Park, Milton Road, Cambridge CB4 0GZ, Great Britain, is assignee of the entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), by reason of an Assignment to the Assignee executed on ✓ 7 December 2000, 8 December 2000 and 11 December 2000 of an invention known as Signal Transduction Protein Involved In Plant Dehiscence (Attorney Docket No. 0623.0890000), which is disclosed and claimed in a patent application of the same title by the inventor(s) Wyatt Paul, Jeremy Alan Roberts, and Catherine Whitelaw (said application filed on September 20, 2000 at the U.S. Patent and Trademark Office, having Application Number 09/646,679, which is the U.S. National Phase of PCT/GB99/00905; international filing date: 22 March 1999).

The Assignee hereby appoints the following U.S. attorneys to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith: Robert Greene Sterne, Esq., Reg. No. 28,912; Edward J. Kessler, Esq., Reg. No. 25,688; Jorge A. Goldstein, Esq., Reg. No. 29,021; Samuel L. Fox, Esq., Reg. No. 30,353; David K.S. Cornwell, Esq., Reg. No. 31,944; Robert W. Esmond, Esq., Reg. No. 32,893; Tracy-Gene G. Durkin, Esq., Reg. No. 32,831; Michele A. Cimbala, Esq., Reg. No. 33,851; Michael B. Ray, Esq., Reg. No. 33,997; Robert E. Sokohl, Esq., Reg. No. 36,013; Eric K. Steffe, Esq., Reg. No. 36,688; Michael Q. Lee, Esq., Reg. No. 35,239; Steven R. Ludwig, Esq., Reg. No. 36,203; Raz E. Fleshner, Esq., Reg. No. 34,331; John M. Covert, Esq., Reg. No. 38,759; and Linda E. Alcorn, Esq., Reg. No. 39,588. The Assignee hereby grants said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

Send correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
U.S.A.

Direct phone calls to 202-371-2600.


FOR: Biogemma UK Limited

SIGNATURE: ✓ [Signature]

BY: ✓ Tina Lorraine Borsky

TITLE: ✓ Company Secretary

DATE: ✓ 18 December 2000



Declaration for Patent Application

Appl. No. 09/646,679
(U.S. Nat'l Phase of PCT/GB99/00905)
Docket Number: 0623.0890000
K&S Ref: KVC/PS/CF/P20895US

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled Signal Transduction Protein Involved in Plant Dehiscence, the specification of which is attached hereto unless the following box is checked:

- ☒ was filed on March 22, 1999 (International Filing Date);
as United States Application Number or PCT International Application Number PCT/GB99/00905 (U.S. Appl. No. 09/646,679); and
was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application, which designated at least one country other than the United States listed below, and have also identified below any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority
Claimed			
<u>9806113.8</u>	<u>Great Britain</u>	<u>20 March 1998</u>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
(Application No.)	(Country)	(Day/Month/Year Filed)	
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
(Application No.)	(Country)	(Day/Month/Year Filed)	

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

_____	_____
(Application No.)	(Filing Date)
_____	_____
(Application No.)	(Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or under § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56 that became available between the filing date of the prior application and the national or PCT international filing date of this application.

<u>PCT/GB99/00905</u>	<u>March 22, 1999</u>	<u>Abandoned</u>
(Application No.)	(Filing Date)	(Status - patented, pending, abandoned)
_____	_____	_____
(Application No.)	(Filing Date)	(Status - patented, pending, abandoned)

Send Correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934

Direct Telephone Calls to:

(202) 371-2600

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor <u>Wyatt Paul</u>	
Signature of sole or first inventor <u>✓</u>	Date <u>✓</u>
Residence Cambridge, Great Britain	
Citizenship Great Britain	
Post Office Address Biogemma UK Limited, 200 Science Park, Milton Road, Cambridge, CB4 0GZ, Great Britain	
Full name of second inventor <u>Jeremy Alan Roberts</u>	
Signature of second inventor <u>✓ J.A. Roberts</u>	Date <u>8/12/00</u>
Residence Leicestershire, Great Britain	
Citizenship Great Britain	
Post Office Address <u>Biosciences R.</u> University of Nottingham, Division of Plant Science, School of Biological Sciences , Sutton Bonington Campus, Loughborough, Leicestershire LE12 5RD , Great Britain <u>GBN</u>	
Full name of third inventor Catherine Whitelaw	
Signature of third inventor <u>✓</u>	Date <u>✓</u>
Residence Beltsville, Maryland	
Citizenship Great Britain	
Post Office Address USDA/ARS/SARL, Room 208, Building 006 BARC-West, 10300 Baltimore Avenue, Beltsville, MD 20705-2350, USA	

P:\USERS\VPChoi\0623\089\declaration.wpd

(Supply similar information and signature for subsequent joint inventors, if any)

Declaration for Patent Application

Appl. No. 09/646,679
(U.S. Nat'l Phase of PCT/GB99/00905)
Docket Number: 0623.0890000
K&S Ref: KVC/PS/CF/P20895US

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled Signal Transduction Protein Involved in Plant Dehiscence, the specification of which is attached hereto unless the following box is checked:

- ☒ was filed on March 22, 1999 (International Filing Date);
as United States Application Number or PCT International Application Number PCT/GB99/00905 (U.S. Appl. No. 09/646,679); and
was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application, which designated at least one country other than the United States listed below, and have also identified below any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s) Claimed	Priority
<u>9806113.8</u> (Application No.)	<u>Great Britain</u> (Country)
	<u>20 March 1998</u> (Day/Month/Year Filed)
	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<u> </u> (Application No.)	<u> </u> (Country)
	<u> </u> (Day/Month/Year Filed)
	<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

<u> </u> (Application No.)	<u> </u> (Filing Date)
<u> </u> (Application No.)	<u> </u> (Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or under § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56 that became available between the filing date of the prior application and the national or PCT international filing date of this application.

<u>PCT/GB99/00905</u> (Application No.)	<u>March 22, 1999</u> (Filing Date)	<u>Abandoned</u> (Status - patented, pending, abandoned)
<u> </u> (Application No.)	<u> </u> (Filing Date)	<u> </u> (Status - patented, pending, abandoned)

Send Correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934

Direct Telephone Calls to:

(202) 371-2600

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Wyatt Paul	
Signature of sole or first inventor ✓	Date ✓
Residence Cambridge, Great Britain	
Citizenship Great Britain	
Post Office Address Biogemma UK Limited, 200 Science Park, Milton Road, Cambridge, CB4 0GZ, Great Britain	
Full name of second inventor Jeremy Alan Roberts	
Signature of second inventor ✓	Date ✓
Residence Leicestershire, Great Britain	
Citizenship Great Britain	
Post Office Address University of Nottingham, Division of Plant Science, School of Biological Sciences, Sutton Bonington Campus, Loughborough, Leicestershire LE12 5RD, Great Britain	
Full name of third inventor Catherine Whitelaw	
Signature of third inventor ✓ <i>C Whitelaw</i>	Date ✓ 11/12/00
Residence Beltsville, Maryland	
Citizenship Great Britain	
Post Office Address USDA/ARS/SARL, Room 208, Building 006 BARC-West, 10300 Baltimore Avenue, Beltsville, MD 20705-2350, USA <i>MV</i>	

P:\USERS\PC\ho\0623\089\declaration vpd

(Supply similar information and signature for subsequent joint inventors, if any)

Declaration for Patent Application

Appl. No. 09/646,679
(U.S. Nat'l Phase of PCT/GB99/00905)
Docket Number: 0623.0890000
K&S Ref: KVC/PS/CF/P20895US

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled Signal Transduction Protein Involved in Plant Dehiscence, the specification of which is attached hereto unless the following box is checked:

- ☒ was filed on March 22, 1999 (International Filing Date);
as United States Application Number or PCT International Application Number PCT/GB99/00905 (U.S. Appl. No. 09/646,679); and
was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application, which designated at least one country other than the United States listed below, and have also identified below any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s) Claimed	Priority
<u>9806113.8</u> (Application No.)	<u>Great Britain</u> (Country)
	<u>20 March 1998</u> (Day/Month/Year Filed)
	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<u> </u> (Application No.)	<u> </u> (Country)
	<u> </u> (Day/Month/Year Filed)
	<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

<u> </u> (Application No.)	<u> </u> (Filing Date)
<u> </u> (Application No.)	<u> </u> (Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or under § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56 that became available between the filing date of the prior application and the national or PCT international filing date of this application.

<u>PCT/GB99/00905</u> (Application No.)	<u>March 22, 1999</u> (Filing Date)	<u>Abandoned</u> (Status - patented, pending, abandoned)
<u> </u> (Application No.)	<u> </u> (Filing Date)	<u> </u> (Status - patented, pending, abandoned)

Send Correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934

Direct Telephone Calls to:

(202) 371-2600

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Wyatt Paul	
Signature of sole or first inventor ✓ W. Paul	Date ✓ 7/12/00
Residence Cambridge, Great Britain	
Citizenship Great Britain	
Post Office Address Biogemma UK Limited, 200 Science Park, Milton Road, Cambridge, CB4 0GZ, Great Britain	
Full name of second inventor Jeremy Alan Roberts	
Signature of second inventor ✓	Date ✓
Residence Leicestershire, Great Britain	
Citizenship Great Britain	
Post Office Address University of Nottingham, Division of Plant Science, School of Biological Sciences, Sutton Bonington Campus, Loughborough, Leicestershire LE12 5RD, Great Britain	
Full name of third inventor Catherine Whitelaw	
Signature of third inventor ✓	Date ✓
Residence Beltsville, Maryland	
Citizenship Great Britain	
Post Office Address USDA/ARS/SARL, Room 208, Building 006 BARC-West, 10300 Baltimore Avenue, Beltsville, MD 20705-2350, USA	

PAUSERS\FCHort0623\089\declaration.wpd

(Supply similar information and signature for subsequent joint inventors, if any)